TWI637745B - 包含蘿蔔硫素或包含一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 - Google Patents
包含蘿蔔硫素或包含一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 Download PDFInfo
- Publication number
- TWI637745B TWI637745B TW106101594A TW106101594A TWI637745B TW I637745 B TWI637745 B TW I637745B TW 106101594 A TW106101594 A TW 106101594A TW 106101594 A TW106101594 A TW 106101594A TW I637745 B TWI637745 B TW I637745B
- Authority
- TW
- Taiwan
- Prior art keywords
- mushroom
- sulforaphane
- extract
- powder
- enzyme
- Prior art date
Links
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 title claims abstract description 386
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims abstract description 248
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 title claims abstract description 177
- 235000015487 sulforaphane Nutrition 0.000 title claims abstract description 177
- 229960005559 sulforaphane Drugs 0.000 title claims abstract description 177
- 239000000284 extract Substances 0.000 title claims abstract description 145
- 239000000843 powder Substances 0.000 title claims abstract description 116
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 239000002243 precursor Substances 0.000 title abstract description 67
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 50
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 42
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 41
- 241000222336 Ganoderma Species 0.000 claims abstract description 34
- 229920002498 Beta-glucan Polymers 0.000 claims description 34
- 229920002307 Dextran Polymers 0.000 claims description 30
- 239000004615 ingredient Substances 0.000 claims description 25
- 229920000310 Alpha glucan Polymers 0.000 claims description 20
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 18
- 230000002195 synergetic effect Effects 0.000 claims description 10
- XQZVZULJKVALRI-UHFFFAOYSA-N 1-isothiocyanato-6-(methylsulfinyl)hexane Chemical compound CS(=O)CCCCCCN=C=S XQZVZULJKVALRI-UHFFFAOYSA-N 0.000 claims description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 3
- 229940096998 ursolic acid Drugs 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 235000001055 magnesium Nutrition 0.000 claims description 2
- ATQQBOJFABGNPX-UHFFFAOYSA-N sulfooxycarbamothioic S-acid Chemical class OS(=O)(=O)ONC(S)=O ATQQBOJFABGNPX-UHFFFAOYSA-N 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 2
- 229940068065 phytosterols Drugs 0.000 claims 2
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims 1
- 244000025272 Persea americana Species 0.000 claims 1
- 235000008673 Persea americana Nutrition 0.000 claims 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 1
- 229960001285 quercetin Drugs 0.000 claims 1
- 235000005875 quercetin Nutrition 0.000 claims 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims 1
- 229960004245 silymarin Drugs 0.000 claims 1
- 235000017700 silymarin Nutrition 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 121
- 108090000790 Enzymes Proteins 0.000 abstract description 121
- 238000000034 method Methods 0.000 abstract description 79
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 abstract description 77
- 235000017647 Brassica oleracea var italica Nutrition 0.000 abstract description 77
- 240000003259 Brassica oleracea var. botrytis Species 0.000 abstract description 73
- 239000003623 enhancer Substances 0.000 abstract description 33
- 235000001715 Lentinula edodes Nutrition 0.000 abstract description 25
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 10
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 9
- 229940088598 enzyme Drugs 0.000 description 119
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 80
- 235000010323 ascorbic acid Nutrition 0.000 description 39
- 239000011668 ascorbic acid Substances 0.000 description 39
- 229960005070 ascorbic acid Drugs 0.000 description 38
- 241000219198 Brassica Species 0.000 description 24
- 235000003351 Brassica cretica Nutrition 0.000 description 24
- 235000003343 Brassica rupestris Nutrition 0.000 description 24
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 24
- 235000010460 mustard Nutrition 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 125000004383 glucosinolate group Chemical group 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 229940011871 estrogen Drugs 0.000 description 16
- 239000000262 estrogen Substances 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 15
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 14
- 244000155437 Raphanus sativus var. niger Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000007888 film coating Substances 0.000 description 12
- 238000009501 film coating Methods 0.000 description 12
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 235000001258 Cinchona calisaya Nutrition 0.000 description 10
- 102000004316 Oxidoreductases Human genes 0.000 description 10
- 108090000854 Oxidoreductases Proteins 0.000 description 10
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229960000948 quinine Drugs 0.000 description 10
- 150000004053 quinones Chemical class 0.000 description 10
- 210000000481 breast Anatomy 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- -1 norbornyl isothiocyanates Chemical class 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 8
- 150000002338 glycosides Chemical class 0.000 description 8
- 229940075071 maitake extract Drugs 0.000 description 8
- 206010005003 Bladder cancer Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 201000005112 urinary bladder cancer Diseases 0.000 description 7
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229920001503 Glucan Polymers 0.000 description 5
- 108010056771 Glucosidases Proteins 0.000 description 5
- 102000004366 Glucosidases Human genes 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 101001109714 Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1 Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 244000308180 Brassica oleracea var. italica Species 0.000 description 4
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 4
- 229920001491 Lentinan Polymers 0.000 description 4
- 241000282376 Panthera tigris Species 0.000 description 4
- 240000001462 Pleurotus ostreatus Species 0.000 description 4
- 241000220259 Raphanus Species 0.000 description 4
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 4
- 231100000357 carcinogen Toxicity 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002036 drum drying Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 150000002540 isothiocyanates Chemical class 0.000 description 4
- 229940115286 lentinan Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 241001506047 Tremella Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 108010058651 thioglucosidase Proteins 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
- 241001327634 Agaricus blazei Species 0.000 description 2
- 244000251953 Agaricus brunnescens Species 0.000 description 2
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 2
- 102000048262 Aldehyde oxidases Human genes 0.000 description 2
- 241000222455 Boletus Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 2
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 2
- 206010006298 Breast pain Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241001070941 Castanea Species 0.000 description 2
- 235000014036 Castanea Nutrition 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020005124 DNA Adducts Proteins 0.000 description 2
- 241001313710 Dictyophora indusiata Species 0.000 description 2
- 102100032682 Dimethylaniline monooxygenase [N-oxide-forming] 2 Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 2
- 229930182735 Ganoderic acid Natural products 0.000 description 2
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 2
- 101710119049 Glutathione peroxidase 3 Proteins 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 2
- 101000795074 Homo sapiens Tryptase alpha/beta-1 Proteins 0.000 description 2
- 244000267823 Hydrangea macrophylla Species 0.000 description 2
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000006662 Mastodynia Diseases 0.000 description 2
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 2
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 2
- 102100026741 Microsomal glutathione S-transferase 1 Human genes 0.000 description 2
- 235000002779 Morchella esculenta Nutrition 0.000 description 2
- 240000002769 Morchella esculenta Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 2
- 244000252132 Pleurotus eryngii Species 0.000 description 2
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 2
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 102100023986 Sulfotransferase 1A1 Human genes 0.000 description 2
- 101710088873 Sulfotransferase 1A1 Proteins 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 241000121220 Tricholoma matsutake Species 0.000 description 2
- 102100029639 Tryptase alpha/beta-1 Human genes 0.000 description 2
- 241000609666 Tuber aestivum Species 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 240000006794 Volvariella volvacea Species 0.000 description 2
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000012682 canthaxanthin Nutrition 0.000 description 2
- 239000001659 canthaxanthin Substances 0.000 description 2
- 229940008033 canthaxanthin Drugs 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108010030727 lens intermediate filament proteins Proteins 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108010074917 microsomal glutathione S-transferase-I Proteins 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- LELAOEBVZLPXAZ-UHFFFAOYSA-N sulfpraphane Natural products CS(=O)CCCN=C=S LELAOEBVZLPXAZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FGYQUFZANKOISC-UHFFFAOYSA-N 5-methylsulfinylpentyl nitrile Chemical compound CS(=O)CCCCC#N FGYQUFZANKOISC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 1
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000006463 Brassica alba Nutrition 0.000 description 1
- 244000140786 Brassica hirta Species 0.000 description 1
- 235000011371 Brassica hirta Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 101150048700 Fcgr3 gene Proteins 0.000 description 1
- 240000006499 Flammulina velutipes Species 0.000 description 1
- 235000016640 Flammulina velutipes Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101001034527 Homo sapiens Glutamate-cysteine ligase catalytic subunit Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 241000222435 Lentinula Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 102100021583 Neurexin-1 Human genes 0.000 description 1
- 101710203761 Neurexin-1 Proteins 0.000 description 1
- JUGSICOHSXBSSM-UHFFFAOYSA-N OC1=C(O)C(=O)C(=O)C=C1 Chemical class OC1=C(O)C(=O)C(=O)C=C1 JUGSICOHSXBSSM-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 240000004370 Pastinaca sativa Species 0.000 description 1
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 description 1
- IPVSUYLZIAYTOK-VWVAXHKFSA-O Peonin Natural products O(C)c1c(O)ccc(-c2c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)cc(O)cc3[o+]2)c1 IPVSUYLZIAYTOK-VWVAXHKFSA-O 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101150071209 TPSB2 gene Proteins 0.000 description 1
- 102000001639 Thioredoxin Reductase 1 Human genes 0.000 description 1
- 108010093836 Thioredoxin Reductase 1 Proteins 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710134953 Tryptase beta-2 Proteins 0.000 description 1
- 102100024060 Type II iodothyronine deiodinase Human genes 0.000 description 1
- 101710100962 Type II iodothyronine deiodinase Proteins 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- GMMLNKINDDUDCF-RFOBZYEESA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-methylsulfinyl-n-sulfooxypentanimidothioate Chemical compound CS(=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-RFOBZYEESA-N 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- LQJARUQXWJSDFL-UHFFFAOYSA-N phenamine Chemical compound CCOC1=CC=C(NC(=O)CN)C=C1 LQJARUQXWJSDFL-UHFFFAOYSA-N 0.000 description 1
- 229950010879 phenamine Drugs 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 150000003675 ursolic acids Chemical class 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01147—Thioglucosidase (3.2.1.147), i.e. myrosinase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
Abstract
本發明係關於一種蘿蔔硫素前驅物、一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、一種酵素增強劑,以及一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合。本發明亦與一種蘿蔔硫素或蘿蔔硫素之一種衍生物及一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合有關。本發明亦與一種青花菜萃取物或青花菜粉末及一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合有關。本發明提供與該些組合有關之組成物及方法。
Description
本申請案主張以下申請案之優先權,各該申請案之全部內容茲列為本申請案之參照:2012年7月5日申請之美國臨時專利申請案61/668,328號、2012年7月5日申請之美國臨時專利申請案61/668,342號、2012年7月5日申請之美國臨時專利申請案61/668,386號、2012年7月5日申請之美國臨時專利申請案61/668,396號、2012年7月5日申請之美國臨時專利申請案61/668,364號、2012年7月5日申請之美國臨時專利申請案61,668,374號,以及2013年3月15日申請之美國臨時專利申請案61/794,417號。
本發明係關於一種蘿蔔硫素前驅物、一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、一種酵素增強劑(enzyme potentiator),以及一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合。本發明亦與一種蘿蔔硫素或蘿蔔硫素之一種衍生物及一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合有關。本發明亦與一種青花菜萃取物或青花菜粉末及一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合有關。本發明提供與該些組合有關之組成物及方法。
天然物的使用在人類及寵物間日漸廣泛。一些天然物會與膳食補充品及醫療用食品結合。本發明所屬技術領域對於可作為化學保護劑及/或抗氧化劑之補充品有所需求。此外,對於可用在乳房相關疾病及失調之醫藥組成物及膳食補充品,本發明所屬技術領域亦有需求。
為預防或減少影響人類及家養動物之許多疾病發生,透過使用天然物以提供化學保護(chemoprotection)正逐漸成為一種安全、有效、價廉、容易取得且實用的方式。目前已知,可在分子等級對細胞造成損害的致癌物,經常以無毒前驅物的形式被攝取及吸入。這些無毒前驅物進入體內後會轉換成致癌物質。化學保護劑,例如可活化去毒酵素或其輔助因子的天然物質,可抵消致癌物及允許致癌物之清除,或增強其他現有的自然防禦機制,例如免疫系統。
某些天然物具有抗氧化活性。氧化壓力(oxidative stress)在老化、神經退化性疾病之進程,以及諸如局部缺血之生理創傷中扮演了主要角色。抗氧化劑可減少或抑制重要維生生物分子的氧化,並可對癌症、冠狀動脈心臟病、中風及神經退化性疾病之治療、預防或減少發生發揮作用,阿滋海默氏症、癡呆及中風為氧化壓力相關疾病之實例。
癌症在很大程度上被認為是曝露於環境刺激--不論來自內部(亦即雌性激素、黃體激素荷爾蒙)或外部(亦即來自塑膠之雙酚A(BPA))--及慢性炎症之結果。幸好,來自環境刺激的損害,可以透過存在於我們體內多種細胞類型中之第二階段化學保護酵素之複雜網絡而消除。眾所周知,雌性激素及其代謝物可導致乳房組織及腫瘤增生。更嚴重的是,該些雌性激素醌類代謝物(quinone estrogen metabolites)能夠進入乳房組織,並
轉移至導管細胞及腺上皮細胞之細胞核內。這些代謝物在細胞核中會與DNA結合,形成會導致下游突變(downstream mutation)之雌性激素醌類DNA鍵結物(DNA adducts)。這些突變被認為是腫瘤,即癌症引發(cancer initiation),的根本原因。幸好,一種特定的第二階段酵素NAD(P)H:quinone oxidoreductase(NQO1)可以處理危險且高反應性之雌性激素醌類化物(quinone estrogens),並將其代謝成易於從身體排除之惰性化學物。因此,減少癌症發生的一個重要機制在於誘發包含NQO1在內之保護性第二階段酵素。增加NQO1之水平,對於治療、預防、修復雌性激素醌類化物之高水平所造成之任何疾病,以及減少此等疾病之發生、減輕此等疾病相關症狀可能有效果。雌性激素醌類化物之實例包含,但不限於,雌性激素之鄰苯二酚醌類化物(catechol quinones)。雌性激素醌類化物在下列參考資料中有述及,各該參考資料之全部內容茲以此述及方式納入本說明書:Nutter等人在Chem Res Toxicol,1994,7:23-28發表之文章;Cavalieri等人在Ann N Y Acad Sci,2006;1089:286-301發表之文章;Bolton等人在Chem Res Toxicol,2008,21(1):93-101發表之文章;以及Cavalieri等人在Biochimica et Biophysica Acta,2006,1766:63-78發表之文章。
蘿蔔硫素(sulforaphane)是被認為具化學保護及抗氧化特性的天然物之一實例。蘿蔔硫素是一種有機硫化合物,又稱1-isothiocyanato-4-methylsulfinylbutane。蘿蔔硫素前驅物,即蘿蔔苷(glucoraphanin),可從十字花科蔬菜中獲得,例如,青花菜、抱子甘藍及甘藍。但要獲得產生化學保護所需的水平,必須食用非常大量的蔬菜。蘿蔔苷係由稱作芥子酵素(myrosinase)的一種硫代葡萄糖苷酵素
(thioglucosidase enzyme)轉換成蘿蔔硫素,該轉換發生於各種外因性來源(例如十字花科蔬菜)及內因性之腸道菌相中。然而,不是所有動物都能在攝取蘿蔔苷後將其轉換成蘿蔔硫素,原因很可能是微生物相及整體健康的變化。此外,在諸如胃等酸性環境中,蘿蔔苷可能被轉換成惰性代謝物。活性代謝物蘿蔔硫素能夠誘發核轉錄因子nuclear factor erythroid-2-related factor(Nrf2),Nrf2會轉而上調(upregulate)第二階段去毒酵素(Phase II detoxification enzymes)及細胞保護酵素(cytoprotective enzymes)的產生,例如,麩胺基硫轉移酵素(glutathione S-transferases)、氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1),以及第一型血基質氧化酵素(heme-oxygenase-1,HO-1)。蘿蔔硫素已被認為可誘發這些酵素產生而不會顯著改變細胞色素P-450的合成。第二階段酵素的上調被認為在各種生物活性中均發揮了作用,包含保護腦部不受細胞毒性影響、保護肝臟不受脂肪蓄積之毒性作用影響,以及其他各種組織之去毒。
蘿蔔硫素及其前驅物蘿蔔苷已受到廣泛研究。Shapiro等人在Nutrition and Cancer,(2006),Vol.55(1),pp.53-62之文章中討論了一項第一階段臨床試驗,該試驗係測定青花菜芽之硫代葡萄糖苷(glucosinolates)及異硫氰酸酯(isothiocyanates)之安全性、耐受性及代謝。Shapiro等人討論以含有硫代葡萄糖苷(例如蘿蔔苷)或異硫氰酸酯(例如蘿蔔硫素)之青花菜芽萃取物,對健康人類受試者所進行的一項有安慰劑控制組、雙盲、隨機之臨床試驗。該試驗發現,給受試者服用這些物質並不會導致系統的、有臨床顯著性之不良反應。Ye等人則在Clinica Chimica Acta,200,316:43-53之文章中討論了青花菜芽之異硫氰酸酯作用於人類時的藥物動力學。
若干種蕈菇因其藥用效果已獲得利用或受到研究。這些「藥用蕈菇」被認為具備有益之特性,例如抗病毒、抗菌、抗癌、抗高血糖,及/或抗發炎之活性。藥用蕈菇之實例包含舞菇、香菇、靈芝、雙孢蘑菇、姬松茸、栗子菇、木耳、毛木耳、牛肝菌、鬼傘、冬蟲夏草、金針菇、鴻喜菇(shimeji)、虎乳靈芝(tiger milk)、羊肚蕈、竹笙、黃金菇、粉紅側耳、杏鮑菇、平茸(hiratake)、繡球菌、銀耳、黃金銀耳、松茸、墨西哥塊菇(Mexican truffle),以及草菇。
舞菇(Grifola frondosa)為可食用菇類,廣泛作為食物而食用,並在傳統醫學中被用於增強免疫功能及治療癌症。含葡聚醣類的舞菇被認為具備有益之特性,例如抗腫瘤及免疫調節之作用。目前已有經標準化處理之舞菇萃取物,其含有有效成分葡聚醣類,例如與蛋白質結合之β-葡聚醣類。一種與蛋白質結合之多醣Beta 1,6-葡聚醣(Beta 1,6-glucan)已被確定為舞菇中之一種活性成分。舞菇已被證明具有腫瘤抑制作用,可在體外(in vitro)抑制腫瘤轉移。在一項試驗中,使用舞菇萃取物之受試者有半數被觀察到腫瘤消退(tumor regression)或症狀顯著改善。在一項更年期乳癌病患之試驗中,給予口服舞菇萃取物顯示具有免疫調節作用。
香菇(Lentinula edodes)是原產於東亞之可食用菇類。香菇含有真菌化學物(mycochemicals),該些化學物具有抗病毒、抗菌、抗發炎、抗高血壓及抗致癌之作用。這點被認為主要是因為葡聚醣類(α-葡聚醣及β-葡聚醣皆是)的緣故。某些香菇萃取物所具有之α-葡聚醣含量超過40%。此外,香菇多糖(1,3 beta-D-glucan),其係從香菇分離出之一種多醣,已經過徹底研究,被認為在香菇的有益效果中發揮了作用。該多醣在大腸癌細胞
中已顯示出具有抗癌作用,這可能是因為該多醣能夠抑制細胞色素P-450 1A酵素,該些酵素已知會將原致癌物代謝成活化形式。香菇中的蛋白質成分香菇多糖(lentin)具有很強的抗真菌特性,且香菇多糖已被發現能夠抑制白血病細胞之增生,及抑制人類免疫不全病毒第一型反轉錄酶(human immunodeficiency virus-1 reverse transcriptase)之活性。
靈芝(Ganoderma lucidum)為在東亞發現之可食用菇類。靈芝被認為具有抗腫瘤、抗癌、免疫調節及免疫治療之作用。靈芝具有若干種被認為有助其活性之成分,包含葡聚醣(例如β-葡聚醣)、斑蝥黄素(canthaxanthin)、固醇類、香豆素(coumarin)、靈芝酸(ganoderic acid),以及甘露醇(mannitol)。
烘培酵母(Saccaromyces cerevisiae)可為葡聚醣類,尤其是β-葡聚醣,之一來源。烘培酵母之有效成分可以數種方式萃取,例如下列參考資料中所述之方法:Bacon等人於Biochem J,1969,114(3):557-567之文章、美國專利7,803,605號;美國專利5,702,719號;及美國專利8,323,644號,各該參考資料之全部內容茲以此述及方式納入本說明書。
葡聚醣類在下列參考資料中有詳述,各該參考資料之全部內容茲以此述及方式納入本說明書:Vetvicka等人在Endocr Metab Immun Disord Drug Targets,2009,9(1):67-75之文章,以及Vetvicka等人在J Med Food,2008:11(4):615-622之文章。
Zhang等人在Proc.Natl.Acad.Sci.,(1994),Vol.91,pp.3147-3150之文章中討論了一項對SD大鼠進行之試驗,以測定蘿蔔硫素及與其結構相關之合成降莰基異硫氰酸酯(norbornyl isothiocyanates)之抗致癌
活性。該試驗測定出,給予服用蘿蔔硫素在阻斷乳腺腫瘤形成方面有效果。
Cornblatt等人在Carcinogenesis,(2007),Vol.38(7):pp.1485-1490之文章中討論了一項對SD大鼠進行之試驗,以測定蘿蔔硫素在乳房中之化學預防效果。該試驗測定出,口服蘿蔔硫素可使乳腺上皮細胞中氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1)之酵素活性增加到三倍,及使第一型血基質氧化酵素(HO-1)之免疫染色提高到四倍。
Munday等人在Cancer Res,(2008),Vol.68(5):pp.1593-1600之文章中討論了一項對大鼠進行之試驗,該試驗係關於青花菜芽之一種冷凍乾燥水萃取物對膀胱癌進展之效應。該試驗發現,給予服用該青花菜芽萃取物可顯著誘發膀胱中的麩胺基硫轉移酵素(glutathione S-transferase)及氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1),該些酵素係對抗氧化物及致癌物具有防護活性之酵素。
Fang等人在J Altern Complem Med,(2006),Vol.12(2):pp.125-132之文章中揭露了一項試驗,以測定香菇中一種乙酸乙酯區分(ethyl acetate fraction)對人類乳癌細胞株(MDA-MB-453及MCF-7)、一種人類非惡性乳房上皮細胞株(MCF-10F),以及兩種骨髓瘤細胞株(RPMI08226及IM-9)之抗增生作用。該試驗發現,腫瘤細胞之生長被香菇中該些成分抑制,可能是細胞凋亡受到誘發所致。
Kim等人在J Med Food,(2007),Vol.10(1):pp.25-31之文章中揭露了一項試驗,以研究自然殺手(natural killer,NK)細胞之活化,以及取自香菇(Lentinus edodes)所培養之米糠之一種胞外生物聚合物(exo-biopolymer)之抗癌作用。該試驗發現,該胞外生物聚合物對於透過
活化自然殺手細胞以預防及/或治療癌症可能有效。
Louie等人在BJUI,(2009),Vol.153(9):pp.1215-1221之文章中,討論了在體外之膀胱癌T24細胞中,α干擾素(interferon-α)與具生物活性之一種蕈菇萃取物,舞菇D-區分(PDF),之組合,對α干擾素之抗癌活性之協同作用。
Masuda等人在Biol.Pharm.Bull.(2008),Vol.31(6):pp.1104-1108之文章中討論了一項試驗,以評定在肺部轉移之一小鼠模式中,舞菇之一區分(fraction)之抗轉移活性。該試驗發現,該區分會以活化自然殺手細胞與抗原呈現細胞(APC),以及抑制黏著分子(例如ICAM-1)之方式抑制腫瘤轉移,從而阻止腫瘤細胞黏著至血管內皮細胞。
歐洲專利申請案2 213 280號揭露了包含硫代葡萄糖苷(例如蘿蔔苷)及芥子酵素之配方,其中該配方係封入膠囊或以膜衣包覆。
本說明書所引用之一切參考資料,其全部內容茲以此述及方式納入本說明書。
本發明提供一種組成物,該組成物包含:(i)一種蘿蔔硫素前驅物,較佳者為蘿蔔苷;(ii)一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素,較佳者為一種葡萄糖苷酵素,更佳者為一種硫代葡萄糖苷酵素,尤佳者為芥子酵素;(iii)一種酵素增強劑,較佳者為抗壞血酸;以及(iv)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦針對癌症,尤其是一受試者之乳癌、前列腺癌、大腸癌、肺癌及膀胱癌,提供一種治療、預防、減少發生、減輕相關症狀,及/或減少二次復發之方
法,該方法包括給予該受試者服用:(i)一種蘿蔔硫素前驅物、(ii)一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、(iii)一種酵素增強劑,以及(iv)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦提供一種使一受試者體內氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1)之水平或基因表現增加之方法,該方法包括給予該受試者服用:(i)一種蘿蔔硫素前驅物、(ii)一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、(iii)一種酵素增強劑,以及(iv)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦針對雌性激素醌類化物水平升高相關之一種疾病或狀況,提供一種治療、預防、減少發生、減輕相關症狀,及/或減少二次復發之方法,該方法包括給予該受試者服用:(i)一種蘿蔔硫素前驅物、(ii)一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、(iii)一種酵素增強劑,以及(iv)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。
本發明提供一種組成物,該組成物包含:(i)蘿蔔硫素或蘿蔔硫素之一種衍生物,以及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦針對癌症,尤其是一受試者之乳癌、前列腺癌、大腸癌、肺癌及膀胱癌,提供一種治療、預防、減少發生、減輕相關症狀,及/或減少二次復發之方法,該方法包括給予該受試者服用:(i)蘿蔔硫素或蘿蔔硫素之一種衍生物,以及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦提供一種使一受試者體內氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1)之水平或基因表現增加之方法,該方法包括給予該受試者服用:(i)蘿蔔硫素或蘿蔔硫素之一種衍生物,以
及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦針對雌性激素醌類化物水平升高相關之一種疾病或狀況,提供一種治療、預防、減少發生、減輕相關症狀,及/或減少二次復發之方法,該方法包括給予該受試者服用:(i)蘿蔔硫素或蘿蔔硫素之一種衍生物,以及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。
本發明提供一種組成物,該組成物包含:(i)一種青花菜萃取物或青花菜粉末,以及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦針對癌症,尤其是一受試者之乳癌、前列腺癌、大腸癌、肺癌及膀胱癌,提供一種治療、預防、減少發生、減輕相關症狀,及/或減少二次復發之方法,該方法包括給予該受試者服用:(i)一種青花菜萃取物或青花菜粉末,以及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦提供一種使一受試者體內氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1)之水平或基因表現增加之方法,該方法包括給予該受試者服用:(i)一種青花菜萃取物或青花菜粉末,以及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。本發明亦針對雌性激素醌類化物水平升高相關之一種疾病或狀況,提供一種治療、預防、減少發生、減輕相關症狀,及/或減少二次復發之方法,該方法包括給予該受試者服用:(i)一種青花菜萃取物或青花菜粉末,以及(ii)一種蕈菇(較佳者為舞菇、香菇或靈芝)萃取物或蕈菇粉末。
圖1為一圖表,其呈現在38℃無抗壞血酸情況下蘿蔔苷之轉換,如實例4所述。
圖2為一圖表,其呈現蘿蔔苷在38℃下大約10分鐘內之轉換作為抗壞血酸濃度之函數,如實例4所述。
圖3為一圖表,其呈現在38℃及1mM抗壞血酸情況下,30分鐘內轉換成之蘿蔔硫素,如實例4所述。
圖4為一圖表,其呈現蘿蔔苷在模擬腸液中轉換成蘿蔔硫素,如實例5所述。
圖5為一圖表,其呈現實例6所述之實驗結果。
圖6為一圖表,其呈現實例7所述之實驗結果。
本發明係關於一種蘿蔔硫素前驅物、一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、一種酵素增強劑,以及一種蕈菇(例如舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合。本發明亦與蘿蔔硫素或蘿蔔硫素之一種衍生物及一種蕈菇(例如舞菇、香菇或靈芝)萃取物或蕈菇粉末之組合有關。本發明亦與一種青花菜萃取物或青花菜粉末及舞菇、香菇或靈芝之一種萃取物或粉末之組合有關。本發明亦與使用一種蕈菇萃取物或蕈菇粉末,並搭配由下列當中一香或多項所混合之物有關:蘿蔔硫素前驅物、蘿蔔硫素或蘿蔔硫素之一種衍生物,及青花菜萃取物。本發明提供與該些組合有關之組成物。
本發明亦提供包含給予服用該些組合之方法。在一些實施例中,可給予一受試者服用該組合,以針對癌症,尤其是該受試者之乳癌、前列腺癌、大腸癌、肺癌及膀胱癌,加以治療、預防、減少發生、減輕相關症狀,及/或減少二次復發。在一些實施例中,可給予一受試者服用該組
合,以增加該受試者體內氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1)之水平或基因表現。在一些實施例中,可給予一受試者服用該組合,以針對雌性激素醌類化物水平升高相關之一種疾病或狀況加以治療、預防、減少發生、減輕相關症狀,及/或減少二次復發。
蘿蔔硫素亦稱1-isothiocyanato-4-methylsulfinylbutane。蘿蔔硫素之衍生物包含但不限於蘿蔔硫素之次硫酸硫代氨基甲酸鹽類似物(sulfoxythiocarbamate analogues)、6-methylsulfinylhexyl isothiocyanate(6-HITC),以及包含蘿蔔硫素結構,但在異硫氰基(isothiocyanato group)及亞碸基(sulfoxide group)間有不同側鏈及/或不同間距基長度之化合物。蘿蔔硫素衍生物之範例包含以下參考資料所述者,各該參考資料之全部內容茲以此述及方式納入本說明書:Hu等人發表於Eur J Med Chem,2013,64:529-539之文章;Ahn等人發表於Proc Natl Acad Sci USA,2010,107(21):9590-9595之文章;Morimistu等人發表於J.Biol.Chem.2002,277:3456-3463之文章;以及Baird等人發表於Arch Toxicol,2011,85(4):241-272之文章。
在一些實施例中,該組成物包含蘿蔔硫素或蘿蔔硫素之一種衍生物,較佳者為蘿蔔硫素,其份量為大約1μg至大約10g,較佳者為大約3μg至大約5g,較佳者為大約5μg至大約1000mg,較佳者為大約7μg至大約750mg,更佳者為大約10μg至大約500mg,尤佳者為大約100μg至大約100mg。在一些實施例中,適於人類使用之組成物包含大約1mg至大約20mg。
在一些實施例中,本發明之方法包含給予一受試者服用蘿蔔
硫素或蘿蔔硫素之一種衍生物,較佳者為蘿蔔硫素,其用量為大約1μg至大約10g,較佳者為大約3μg至大約5g,較佳者為大約5μg至大約1000mg,較佳者為大約7μg至大約750mg,更佳者為大約10μg至大約500mg,尤佳者為大約100μg至大約100mg。在受試者為人類之一些實施例中,該方法包含給予受試者服用大約1mg至大約20mg。在一些實施例中,本發明之方法包含給予一受試者服用蘿蔔硫素或蘿蔔硫素之一種衍生物,較佳者為蘿蔔硫素,其用量為大約0.01μg/kg至大約0.2g/kg,較佳者為大約0.05μg/kg至大約0.07g/kg,更佳者為大約0.07μg/kg至大約15mg/kg,更佳者為大約0.1μg/kg至大約11mg/kg,尤佳者為大約0.2μg/kg至大約7mg/kg。在受試者為人類之一些實施例中,該方法包含給予受試者服用大約2μg/kg至大約2mg/kg之用量,更佳者為大約0.01mg/kg至大約0.3mg/kg之用量。上述該些用量可指每劑服用之量或每日總劑量。每日總劑量係指在24小時內給予一受試者服用之一種化合物或成分之總量。
在一些實施例中,該方法包含給予服用一種蘿蔔硫素或蘿蔔硫素之一種衍生物當中不只一者。在一些實施例中,該些組成物包含一種蘿蔔硫素或蘿蔔硫素之一種衍生物當中不只一者。舉例而言,該些方法或組成物可同時包含蘿蔔硫素及蘿蔔硫素之一種或多種衍生物,或同時包含兩種或更多種衍生物。在一些實施例中,當該方法或組成物包含一種蘿蔔硫素或蘿蔔硫素之一種衍生物當中不只一者時,上文所述之量可指每種蘿蔔硫素或每一種蘿蔔硫素衍生物各別之量,或指不只一種之蘿蔔硫素或蘿蔔硫素衍生物之總量。
在本說明書中,「蘿蔔硫素前驅物」一詞係指可用於生產蘿
蔔硫素之任何化合物、物質或原料。在較佳實施例中,該蘿蔔硫素前驅物包含可被轉換或代謝成蘿蔔硫素之一種化合物,較佳者為由一種酵素轉換或代謝成蘿蔔硫素。在一些較佳實施例中,該蘿蔔硫素前驅物包含蘿蔔苷。蘿蔔苷為一種硫代葡萄糖苷(glucosinolate),亦稱4-methylsulfinylbutyl glucosinolate及1-S-[(1E)-5-(methylsulfinyl)-N-(sulfonatooxy)pentanimidoyl]-1-thio-β-D-glucopyranose。
在一些實施例中,該組成物包含該蘿蔔硫素前驅物,較佳者為蘿蔔苷,其份量為大約1μg至大約10g,較佳者為大約250μg至大約5g,更佳者為大約500μg至大約2000mg,甚佳者為大約1mg至大約750mg,再甚佳者為大約1.5mg至大約250mg,更甚佳者為大約2mg至大約100mg,尤佳者為大約3mg至大約75mg。在一些實施例中,適於人類使用之組成物包含大約3.5mg至大約50mg之該蘿蔔硫素前驅物,較佳者為蘿蔔苷。
在一些實施例中,該方法包含給予一受試者服用該蘿蔔硫素前驅物,較佳者為蘿蔔苷,其份量為大約1μg至大約10g,較佳者為大約250μg至大約5g,更佳者為大約500μg至大約2000mg,甚佳者為大約1mg至大約750mg,再甚佳者為大約1.5mg至大約250mg,更甚佳者為大約2mg至大約100mg,尤佳者為大約3mg至大約75mg。在受試者為人類之一些實施例中,該方法包含給予受試者服用大約3.5mg至大約50mg。在一些實施例中,該方法包含給予一受試者服用一份量之蘿蔔硫素前驅物,其用量為大約1μg/kg至大約1000mg/kg,較佳者為大約5μg/kg至大約500mg/kg,更佳者為大約7.5μg/kg至大約100mg/kg,甚佳者為大約10μg/kg至大約25mg/kg,尤佳者為大約25μg/kg至大約10mg/kg。在受試者為人類之一些實施例中,該
方法包含以大約50μg/kg至大約800μg/kg之用量給予服用。上述該些用量可指每劑服用之量或指每日總劑量。
在一些實施例中,該方法包含給予服用不只一種蘿蔔硫素前驅物。在一些實施例中,該組成物包含不只一種蘿蔔硫素前驅物。在一些實施例中,當該方法或組成物包含不只一種蘿蔔硫素前驅物時,上述該些用量可指每一種蘿蔔硫素前驅物之量,或指該些蘿蔔硫素前驅物之總量。
該蘿蔔硫素前驅物可被轉換或代謝成蘿蔔硫素。在一些實施例中,該蘿蔔硫素前驅物係由一種酵素轉換成蘿蔔硫素。在一些實施例中,能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之該酵素包含一種葡萄糖苷酵素(glucosidase enzyme),較佳者為一種硫代葡萄糖苷酵素(thioglucosidase enzyme),更佳者為芥子酵素。芥子酵素亦稱硫代葡萄糖苷醣類水解酵素(thioglucoside glucohydrolase)。
在一些實施例中,該組成物包含該酵素之量為大約1pg至大約1μg,較佳者為大約50pg至大約500ng,尤佳者為大約1ng至大約150ng。在一些實施例中,適於人類使用之組成物包含大約5ng至大約75ng之該酵素。
在一些實施例中,該方法包含以大約1pg至大約1μg,較佳者為大約50pg至大約500ng,尤佳者為大約1ng至大約150ng之量給予服用該酵素,較佳者為芥子酵素。在受試者為人類之一些實施例中,該方法包含給予服用大約5ng至大約75ng之該酵素。在一些實施例中,該方法包含給予一受試者服用該酵素,其用量為大約0.02pg/kg至大約0.02ug/kg,較佳者為大約0.7pg/kg至大約7ng/kg,尤佳者為大約0.02ng/kg至大約2ng/kg。
在受試者為人類之一些較佳實施例中,該方法包含以大約0.1ng/kg至大約1ng/kg之量給予服用。上述該些用量可指每劑服用之量或每日總劑量。
在一些實施例中,該方法包含給予服用不只一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素。在一些實施例中,該組成物包含不只一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素。在一些實施例中,當該些方法或組成物包含不只一種酵素時,上述該些用量可指每一種酵素之量,或指該些酵素之總量。
本發明亦提供一種青花菜萃取物及/或青花菜粉末之使用,包含但不限於青花菜種子及青花菜芽之萃取物及粉末。本發明提供給予服用青花菜萃取物及/或青花菜粉末之方法,以及包含青花菜萃取物及/或青花菜粉末之組成物。在一些實施例中,該青花菜萃取物或青花菜粉末經過標準化處理,使之包含大約1%至大約75% w/w,更佳者為大約2.5%至大約50% w/w,甚佳者為大約5%至大約25% w/w,尤佳者為大約10%至大約20% w/w之一種蘿蔔硫素前驅物,較佳者為蘿蔔苷。青花菜萃取物及青花菜粉末之範例包含但不限於美國專利5,411,986號;5,725,895號;5,968,505號;5,968,567號;6,177,122號;6,242,018號;6,521,818號;7,303,770號及8,124,135號所述者,各該專利之全部內容茲以此述及方式納入本說明書。青花菜粉末可經由將青花菜,較佳者為青花菜芽,舉例而言,風乾、冷凍乾燥、滾筒乾燥、噴霧乾燥、加熱乾燥及/或部分真空乾燥而獲得。在一些實施例中,該些組成物及方法包含使用大約1μg至大約10g,更佳者為大約250μg至大約5g,甚佳者為大約500μg至大約1g,較佳者為大約600μg至大約500mg,更佳者為大約750μg至大約400mg,尤佳者為大約1mg至大約300mg之該
青花菜萃取物。在一些實施例中,該青花菜萃取物或青花菜粉末係存在於一組成物中,或係以足夠提供上述該些份量之一種蘿蔔硫素前驅物或蘿蔔硫素之量,而給予一受試者服用。在一些實施例中,該組成物可更包含一種酵素增強劑,較佳者為抗壞血酸。在一些實施例中,該方法可更包含給予服用一種酵素增強劑,較佳者為抗壞血酸。
蘿蔔硫素或蘿蔔硫素之一種衍生物、該蘿蔔硫素前驅物,及/或能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之該酵素,可取自任何來源,包含但不限於十字花科(亦稱蕓薹科)之一種或多種植物。十字花科植物之範例包含但不限於以下所列者:青花菜、抱子甘藍、花椰菜、甘藍、辣根、歐洲防風、蘿蔔、山葵、水田芥及白芥菜。在一些較佳實施例中,蘿蔔硫素前驅物,較佳者為蘿蔔苷,以及該酵素,較佳者為芥子酵素,係取自青花菜、青花菜芽或青花菜種子。該蘿蔔硫素前驅物及該酵素可取自相同來源或不同來源。在一些實施例中,該蘿蔔硫素前驅物及該酵素可皆取自該些植物之一種萃取物或粉末,較佳者為青花菜種子或青花菜芽之一種萃取物或粉末。
本發明提供一種酵素增強劑之使用。酵素增強劑可用於加強能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之該酵素之活性。在一些實施例中,該酵素增強劑包含一種酵素輔助因子,較佳者為抗壞血酸。抗壞血酸,亦稱抗壞血酸鹽或維生素C,可增強芥子酵素之活性。在一些實施例中,當沒有諸如抗壞血酸之酵素增強劑存在時,轉換成蘿蔔硫素之反應可能會太慢,以致無法在最大吸收(peak absorption)所需之位置發生。該酵素增強劑可取自一天然來源或以合成方式生產。
在一些實施例中,該些組成物可包含大約1mg至大約500mg,較佳者為大約1mg至大約250mg,尤佳者為大約1mg至大約125mg之該酵素增強劑。在一些實施例中,適於人類使用者組成物包含大約1mg至大約50mg之該酵素增強劑。
在一些實施例中,本發明之方法包含以大約1mg至大約500mg,較佳者為1mg至大約250mg,尤佳者為大約1mg至大約125mg之量,給予服用一種酵素增強劑,較佳者為抗壞血酸。在受試者為人類之一些實施例中,該方法包含給予服用大約1mg至大約50mg。在一些實施例中,本發明之方法包含以大約0.01mg/kg至大約3mg/kg,尤佳者為大約0.02mg/kg至大約2mg/kg之量,給予服用該酵素增強劑,較佳者為抗壞血酸。在受試者為人類之一些實施例中,該方法包含以大約0.02mg/kg至大約0.7mg/kg之量給予服用該酵素增強劑。上述該些用量可指每劑服用之量或每日總劑量。
在一些實施例中,該方法包含給予服用不只一種酵素增強劑。在一些實施例中,該組成物包含不只一種酵素增強劑。在一些實施例中,當該方法或組成物包含不只一種酵素增強劑時,上述該些用量可指每一種酵素增強劑之量,或指該些酵素增強劑之總量。
本發明提供一種蕈菇萃取物或蕈菇粉末之使用。在一些實施例中,該些蕈菇可包含「藥用蕈菇」,其包含但不限於,舞菇、香菇、靈芝、雙孢蘑菇、姬松茸、栗子菇、木耳、毛木耳、牛肝菌、鬼傘、冬蟲夏草、金針菇、鴻喜菇(shimeji)、虎乳靈芝(tiger milk)、羊肚蕈、竹笙、黃金菇、粉紅側耳、杏鮑菇、平茸(hiratake)、繡球菌、銀耳、黃金銀耳、松茸、墨西哥塊菇(Mexican truffle),以及草菇。在較佳實施例中,該蕈菇包含舞菇、
香菇、靈芝,及/或前述當中一者或多者之混合。
舞菇屬於灰樹花(Grifola frondosa)種。舞菇可含有具生物活性之數種成分。在舞菇中發現之成分實例包含但不限於:葡聚醣類(例如α-葡聚醣及β-葡聚醣);脂類(例如硬脂酸及亞麻油酸);磷脂類(例如磷脂醯乙醇胺(phosphatidylethanolamine)、卵磷脂、磷脂醯肌醇(phosphatidylinositol)、磷脂醯絲胺酸(phosphatidylserine)及磷脂酸)。
香菇屬於香菇(Lentinula edodes)種。香菇可含有具生物活性之數種成分。在香菇中發現之成分實例包含但不限於:葡聚醣類(例如α-葡聚醣及β-葡聚醣);蛋白質(例如香菇多糖(lentin));脂類(例如亞麻油酸);以及木質素。
靈芝屬於靈芝(Ganoderma lucidum)種。靈芝可含有具生物活性之數種成分。在靈芝中發現之成分實例包含但不限於:葡聚醣類(例如α-葡聚醣及β-葡聚醣)、斑蝥黄素(canthaxanthin)、固醇類、香豆素(coumarin)、靈芝酸(ganoderic acid),以及甘露醇(mannitol)。
在一些較佳實施例中,該蕈菇萃取物或蕈菇粉末包含一種或多種葡聚醣。葡聚醣是由醣苷鍵(glycosidic bonds)連接的D-葡萄糖單體(D-glucose monomer)所組成之一種多醣,葡聚醣可為α或β形式。在一些實施例中,該葡聚醣包含一種或多種α-葡聚醣及/或β-葡聚醣。α-葡聚醣包含但不限於1,4-α-葡聚醣及1,6-α-葡聚醣,β-葡聚醣包含但不限於1,3-β-葡聚醣、1,4-β-葡聚醣,以及1,6-β-葡聚醣。該些葡聚醣可以各種不同之聚合物組構表現。在較佳實施例中,該舞菇萃取物或舞菇粉末包含1,3-β-葡聚醣及/或1,6-β-葡聚醣。在較佳實施例中,該香菇萃取物或香菇粉末包含1,4-α-葡聚
醣。在較佳實施例中,該靈芝萃取物或靈芝粉末包含1,3-β-葡聚醣及/或1,6-β-葡聚醣。在一些實施例中,本發明之該些組成物及方法可包含使用純化形式或合成方式生產之葡聚醣類,而非使用一種蕈菇萃取物或蕈菇粉末。
在一些實施例中,可使用一種舞菇萃取物或舞菇粉末。在一些實施例中,該舞菇萃取物或舞菇粉末係經過標準化處理,以包含大約1%至大約75%,更佳者為大約5%至大約50%,甚佳者為大約10%至大約30%,尤佳者為大約15%至大約20%之一種或多種葡聚醣,較佳者為β-葡聚醣,更佳者為1,3-β-葡聚醣及/或1,6-β-葡聚醣。舞菇萃取物或舞菇粉末之實例包含但不限於美國專利5,854,404號;國際專利WO 2007142130號;歐洲專利EP 0893449號;國際專利WO2009063885號;國際專利WO2006107208號;國際專利WO2007024496號;以及國際專利WO2001054673號所述者,各該專利之全部內容茲以此述及方式納入本說明書。舞菇粉末可經由將舞菇,舉例而言,風乾、冷凍乾燥、滾筒乾燥、噴霧乾燥、加熱乾燥及/或部分真空乾燥而獲得。在一些實施例中,該組成物包含大約250μg至大約100mg,較佳者為500μg至大約75mg,尤佳者為大約750μg至大約50mg。在一些實施例中,適於人類使用之組成物包含大約1mg至大約20mg之舞菇萃取物。在一些實施例中,該方法包含給予服用大約250μg至大約100mg,較佳者為500μg至大約75mg,尤佳者為大約750μg至大約50mg。在受試者為人類之一些較佳實施例中,該方法包含給予服用大約1mg至大約20mg之舞菇萃取物。上述該些用量可指每劑服用之量或每日總劑量。
在一些實施例中,可使用一種香菇萃取物或香菇粉末。在一些實施例中,該香菇萃取物或香菇粉末係經過標準化處理,以包含大約1%
至大約75%,較佳者為大約10%至大約60%,甚佳者為大約25%至大約50%,尤佳者為大約30%至大約40%之一種或多種葡聚醣,較佳者為α-葡聚醣,更佳者為1,4-α-葡聚醣。香菇萃取物或香菇粉末之實例包含但不限於美國專利5,780,097號;美國專利6,582,723號;國際專利WO2005107496號、國際專利WO2007024496號,以及國際專利WO2000033069號所述者,各該專利之全部內容茲以此述及方式納入本說明書。舞菇粉末可經由將舞菇,舉例而言,風乾、冷凍乾燥、滾筒乾燥、噴霧乾燥、加熱乾燥及/或部分真空乾燥而獲得。在一些實施例中,該組成物包含大約1mg至大約1g,較佳者為大約10mg至大約500mg,尤佳者為大約25mg至大約300mg。在一些實施例中,適於人類使用之組成物包含大約50mg至大約250mg之香菇萃取物或香菇粉末。在一些實施例中,該方法包含給予服用大約1mg至大約1g,較佳者為大約10mg至大約500mg,尤佳者為大約25mg至大約300mg。在受試者為人類之一些較佳實施例中,該方法包含給予一受試者服用大約50mg至大約250mg之香菇萃取物或香菇粉末。上述該些用量可指每劑服用之量或每日總劑量。
在一些實施例中,可使用一種靈芝萃取物或靈芝粉末。在一些實施例中,該靈芝萃取物或靈芝粉末包含大約1%至大約75%,更佳者為大約5%至大約50%,甚佳者為大約10%至大約30%,尤佳者為大約15%至大約20%之一種或多種葡聚醣,較佳者為β-葡聚醣,更佳者為1,3-β-葡聚醣及/或1,6-β-葡聚醣。舞菇粉末可經由將舞菇,舉例而言,風乾、冷凍乾燥、滾筒乾燥、噴霧乾燥、加熱乾燥及/或部分真空乾燥而獲得。
在一些實施例中,該組成物及/或方法包含使用一種蕈菇萃
取物或蕈菇粉末,例如舞菇萃取物或舞菇粉末、香菇萃取物或香菇粉末,或靈芝萃取物或靈芝粉末。在一些實施例中,該組成物及/或方法包含使用由一種或多種蕈菇萃取物或蕈菇粉末所混合之物。在一些實施例中,該組成物及/或方法包含使用由下列當中一項或多項所混合之物:舞菇萃取物或舞菇粉末、香菇萃取物或香菇粉末,以及靈芝萃取物或靈芝粉末。該組成物及方法可包括使用一種萃取物或一種粉末,或由多種萃取物及粉末所混合之物。
本發明亦使用以富含葡聚醣之任何成分代替該蕈菇萃取物或蕈菇粉末,或是除該蕈菇萃取物或蕈菇粉末,還使用富含葡聚醣之任何成分。富含葡聚醣之成分之一實例為烘培酵母。在一些實施例中,可使用酵母製劑。在一些實施例中,該酵母製劑包含大約0.1%至大約50%,較佳者為大約0.5%至大約25%,尤佳者為大約0.5%至大約10%之一種或多種葡聚醣。酵母製劑之實例包含美國專利5,223,491號及美國專利5,576,015號所討論者,各該專利之全部內容茲以此述及方式納入本說明書。
本發明之方法可更包含給予服用一種或多種額外成分。本發明之組成物可更包含一種或多種額外成分。該些額外成分可包含有效藥劑成分、營養補充劑及營養萃取物。額外成分之實例包含,但不限於,熊果酸、檞皮素或檞皮素之一種衍生物、一種胺基糖,例如葡萄糖胺、一種葡萄胺聚醣,例如軟骨素、鱷梨/大豆之不皂化物、維生素,例如維生素K2、咖啡果實、鎂、熊果酸、原花青素、α-及β-葡聚醣、薑黃素、植物固醇、植物固烷醇,以及S-腺苷甲硫胺酸(SAMe)。這些額外成分可存在於奶薊(Silybum marianum)之萃取物(水飛薊素)、蔓越橘(Vaccinium macrocarpon)
之萃取物(原花青素、檞皮素及熊果酸)、薑黃(Curcuma longa)中。
在一些實施例中,β-葡聚醣與蘿蔔硫素或蘿蔔硫素之一種衍生物之比(β-葡聚醣:蘿蔔硫素或蘿蔔硫素之一種衍生物)為大約50:1至大約1:50,較佳者為大約25:1至大約1:25,更佳者為大約10:1至大約1:20,再更佳者為大約5:1至大約1:10,甚佳者為大約1:1至大約1:8,尤佳者為大約1:3至大約1:5。在一些實施例中,α-葡聚醣與蘿蔔硫素或蘿蔔硫素之一種衍生物之比(α-葡聚醣:蘿蔔硫素或蘿蔔硫素之一種衍生物)為大約1:50至大約50:1,較佳者為大約1:10至大約25:1,更佳者為大約1:5至大約20:1,再更佳者為大約1:1至大約15:1,甚佳者為大約2:1至大約10:1,尤佳者為大約3:1至大約8:1。在一些實施例中,β-葡聚醣與蘿蔔硫素前驅物之比(β-葡聚醣:蘿蔔硫素前驅物)為大約50:1至大約1:50,較佳者為大約30:1至大約1:35,更佳者為大約20:1至大約1:25,再更佳者為大約10:1至大約1:20,甚佳者為大約5:1至大約1:15,尤佳者為大約1:1至大約1:10。在一些實施例中,α-葡聚醣與蘿蔔硫素前驅物之比(α-葡聚醣:蘿蔔硫素前驅物)為大約1:50至大約100:1,較佳者為大約1:25至大約75:1,更佳者為大約1:10至大約50:1,再更佳者為大約1:5至大約40:1,甚佳者為大約1:1至大約30:1,尤佳者為大約2:1至大約20:1。
在一些實施例中,該組成物包含一種單位劑量形式,其包含但不限於適合口服、直腸給藥、靜脈給藥、皮下給藥、肌內給藥、經皮給藥、經黏膜給藥及局部給藥之醫藥劑量形式。在一些較佳實施例中,該組成物包含一種口服劑型或一種直腸給藥劑型。口服劑型之範例包含但不限
於藥錠、膠囊、可分散於飲料中之粉末、一種液體,例如溶液、懸浮液或乳劑、一種軟膏/咀嚼膠囊、一種咀嚼棒,或本發明所屬技術領域中已知之其他合適劑型。在較佳實施例中,該組成物包含一種藥錠、膠囊或柔軟之咀嚼點心。該些口服劑型可製備成快速釋放、持續釋放或延遲釋放。
在一些實施例中,用於提供至少該蘿蔔硫素前驅物、該酵素及該酵素增強劑之劑型,係能夠在消化道中具有pH值至少為4之一區域,較佳者為具有pH值至少為5之一區域釋放者,例如小腸,較佳者為十二指腸。在一些實施例中,用於提供至少該蘿蔔硫素或蘿蔔硫素衍生物,及/或該青花菜萃取物或青花菜粉末之劑型,係能夠在消化道中具有pH值至少為4之一區域,較佳者為具有pH值至少為5之一區域釋放者,例如小腸,較佳者為十二指腸。在一些實施例中,該蕈菇萃取物或蕈菇粉末,以及/或任何選擇性額外成分被釋放之區域,亦是在消化道中具有pH值至少為4之一區域,較佳者具有pH值至少為5之一區域,例如小腸,較佳者為十二指腸。前文所述之小腸包含十二指腸、空腸及迴腸。
在一些實施例中,每一種成分(亦即蘿蔔硫素前驅物、酵素、酵素增強劑、蘿蔔硫素或蘿蔔硫素之一種衍生物、青花菜萃取物或青花菜粉末、蕈菇萃取物或蕈菇粉末,及/或額外成分)係同時釋放或相伴釋放(亦即在一短時間內彼此伴隨釋放)。這種方式優於被製備成在消化道中具有pH值低於4之一區域(例如胃)釋放之含蘿蔔苷之組成物。因在此種低pH值環境下,其酸性環境會將蘿蔔硫素前驅物改而轉換成生理上非活性之其他最終產物,例如蘿蔔硫腈(sulforaphane nitrile)及環硫腈(epithionitrile)。
在一些實施例中,該些組成物可包括口服組成物,其包含腸
溶膜衣劑型或可耐受消化道中pH值低於4之一區域(例如胃)之降解之任何劑型。舉例而言,該口服組成物可包括含腸溶膜衣之一藥錠或膠囊。該腸溶膜衣所包括之材料可包含但不限於乙醯醋酸纖維素(cellulose acetate phthalate)、鄰苯二甲酸羥丙基甲基纖維素(hydroxypropyl methylcellulose phthalate)、聚乙烯醋酸纖維素(polyvinyl acetate phthalate)、甲基丙烯酸共聚物(methacrylic acid copolymer)、甲基丙烯酸:丙烯酸酯共聚物(methacrylic acid:acrylic ester copolymer)、羥丙基甲基纖維素琥珀酸醋酸鹽(hydroxypropyl methylcellulose acetate succinate)、羥丙基甲基纖維素偏苯三甲酸酯(hydroxypropyl methylcellulose trimellitate)、蟲膠(shellac)、乙酸偏苯三甲酸酯纖維素(cellulose acetate trimellitate)、羧甲基乙基纖維素(carboxymethylethylcellulose),及由前述者混合之物。該腸溶膜衣可包含本發明所屬技術領域中已知之任何合適之腸溶性聚合物。在一些實施例中,該組成物中該些成分之一種或多種可嵌入腸溶性聚合物之一基質。在一些實施例中,該些口服組成物包含會在胃酸中緩慢溶解並移動至小腸之一種耐酸膠囊,例如CAPSUGEL®所銷售之DRCAPSTM耐酸膠囊,或其他任何耐酸膠囊。
在最佳形式下,該口服組成物係被一膜衣所圍住,該膜衣只會在周圍介質之pH值至少為4,更佳者為pH值至少為5,時才會溶解。作為一替代方案,可採用以時間而非pH值來控制釋放之一種膜衣,其釋放速率被調整至只有在消化道之pH值上升到至少為4,更佳者為上升到至少為5,該些成分才會被釋放。因此,一種按時間釋放(緩釋)之配方可用於防止該蘿蔔硫素前驅物、能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之該酵素及
該酵素增強劑,或是防止該蘿蔔硫素,在胃部釋放。該(些)膜衣層可以標準包覆技術應用於口服組成物。該些腸溶膜衣之材料可溶解或分散於有機溶劑或水溶劑中。使該腸溶膜衣開始溶解之pH值,可經由具選定之側鏈基及/或側鏈基比率之一種聚合物或多種聚合物之組合加以控制。舉例而言,該聚合物膜之溶解特性可經由調整游離羧基與酯基之比而加以改變。腸溶膜衣層亦含有醫藥上可接受之塑化劑,例如檸檬酸三乙酯(triethyl citrate)、鄰苯二甲酸二丁酯(dibutyl phthalate)、三醋汀(triacetin)、聚乙二醇(polyethylene glycols)、聚山梨醇酯(polysorbates)或其他塑化劑。添加物亦可包含在內,例如分散劑、著色劑、抗黏著劑及抗發泡劑。
該些組成物可含有一種或多種非有效藥劑成分(通常亦稱「賦形劑」)。非有效成分,舉例而言,係用於溶解化、懸浮、稠化、稀釋、乳化、安定、保存、保護、著色、調味及形成該些有效成分,使其成為可適用及有效之一種製劑,該製劑是安全、方便並在其他方面可以使用的。該些賦形劑最好為醫藥上可接受之賦形劑。醫藥上可接受之賦形劑類別之範例包含潤滑劑、緩衝劑、安定劑、發泡劑、色素、著色劑、調味劑、充填劑、增積劑、香料、釋出修飾劑(release modifiers)、佐劑、塑化劑、流加速劑(flow accelerators)、離型劑、多元醇、造粒劑(granulating agents)、稀釋劑、黏合劑、緩衝劑、吸收劑、滑動劑、黏著劑、抗黏劑、酸化劑、軟化劑、樹脂、緩和劑、溶劑、表面活性劑、乳化劑、彈性體,及由前述者混合之物。
在一些實施例中,(i)一種蘿蔔硫素前驅物,較佳者為蘿蔔苷、(ii)一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素,較佳者為
一種葡萄糖苷酵素,更佳者為一種硫代葡萄糖苷酵素,尤佳者為芥子酵素、(iii)一種酵素增強劑,較佳者為一種酵素輔助因子,更佳者為抗壞血酸,以及(iv)一種蕈菇萃取物或蕈菇粉末(其含有葡聚醣)之組合,表現出協同作用。在一些實施例中,蘿蔔硫素(或蘿蔔硫素之一種衍生物)及一種蕈菇萃取物或蕈菇粉末(其含有葡聚醣)之組合表現出協同作用。協同作用係指兩種或更多種成分之組合所提供之效果,大於該些作用物單獨使用時所產生效果之總和。在較佳實施例中,該協同作用大於累加作用。在一些實施例中,一種蘿蔔硫素前驅物、一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、一種酵素增強劑,以及舞菇、香菇或靈芝之一種萃取物或粉末之組合,相較於下列情況而有具統計顯著性之較大效果:(i)僅有各單獨成分,(ii)僅有該蘿蔔硫素前驅物及該酵素之組合;及/或(iii)僅有該蘿蔔硫素前驅物、該酵素及該酵素增強劑之組合。
在較佳實施例中,該蘿蔔硫素前驅物、該酵素、該酵素增強劑,以及一種蕈菇萃取物或蕈菇粉末(其含有葡聚醣)之組合,因相較於僅有該蘿蔔硫素前驅物及僅有該蕈菇萃取物或蕈菇粉末之情況,顯示出有統計顯著性及/或大於累加之效應而證明其協同作用。在一些實施例中,相較於僅有蘿蔔苷、芥子酵素、抗壞血酸之組合,以及相較於僅有葡聚醣類之情況,蘿蔔苷、芥子酵素、抗壞血酸及一種蕈菇萃取物或蕈菇粉末之組合具有協同作用。
在一些實施例中,一種蘿蔔硫素(或蘿蔔硫素之一種衍生物)及一種蕈菇萃取物或蕈菇粉末之組合,較下列情況有統計顯著性及/或大於累加之效應:(i)僅有蘿蔔硫素(或蘿蔔硫素之一種衍生物),及/或(ii)僅
有一種蕈菇萃取物或蕈菇粉末。在一些實施例中,相較於僅有蘿蔔硫素及僅有葡聚醣之情況,蘿蔔硫素及葡聚醣之組合具有協同作用。
在一些實施例中,青花菜萃取物或青花菜粉末及一種蕈菇萃取物或蕈菇粉末之組合,較下列情況有統計顯著性及/或大於累加之效應:(i)僅有青花菜萃取物或青花菜粉末,及/或(ii)僅有一種蕈菇萃取物或蕈菇粉末。在一些實施例中,相較於僅有青花菜萃取物或青花菜粉末及僅有葡聚醣之情況,青花菜萃取物或青花菜粉末及葡聚醣之組合具有協同作用。
本發明提供使用之方法,其包含給予有需要之一受試者服用之方法。在一些實施例中,該方法包含給予服用一種蘿蔔硫素前驅物、一種能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之酵素、一種酵素增強劑,以及一種蕈菇萃取物或蕈菇粉末之組合。在一些實施例中,該方法包含給予服用一種蘿蔔硫素或蘿蔔硫素之一種衍生物及一種蕈菇萃取物或蕈菇粉末之組合。在一些實施例中,該方法包含給予服用一種青花菜萃取物或青花菜粉末及一種蕈菇萃取物或蕈菇粉末之組合。
在一些實施例中,該方法係關於針對癌症,尤其是一受試者之乳癌、前列腺癌、大腸癌、肺癌及膀胱癌,加以治療、預防、減少發生、減輕相關症狀,及/或減少二次復發。該些方法可有助降低或延緩對組織及器官之損害,例如對乳房、前列腺、大腸、肺臟、肝臟及膀胱之損害。本發明提供針對生殖系統(包含但不限於乳房及前列腺)、大腸、肝臟、膀胱、腎臟、中樞神經系統、心血管系統、肺系統、生殖泌尿系统、造血系統及關節相關疾病及狀況,加以治療、預防、減輕相關症狀,及/或減少二次復發之方法。本發明亦提供針對囊腫(例如良性囊腫)加以治療、預防、減
輕相關症狀,及/或減少二次復發之方法。
在一些實施例中,該方法與增加一受試者體內氧化還原酵素NAD(P)H:quinine oxidoreductase(NQO1)之水平或基因表現有關。對於會從NQO-1之水平或基因表現增加而獲益之疾病及狀況而言,該方法亦可有助於此等疾病及狀況之治療、預防、減輕相關症狀及/或減少二次復發。此等疾病及狀況之實例包括,但不限於,癌症、骨髓化生不良症候群(myelodysplastic syndrome)、心血管疾病,以及遲發性運動障礙(tardive dyskinesia)。
在一些實施例中,該方法係關於針對雌性激素醌類化物水平升高相關之一種疾病或狀況,加以治療、預防、減少發生、減輕相關症狀,及/或減少二次復發。此等疾病或狀況之實例包括,但不限於,癌症、骨髓化生不良症候群、心血管疾病,以及遲發性運動障礙。
在一些實施例中,該些方法係關於為生物標記提供有益之影響,以及針對這些生物標記之異常水平加以治療、預防、減少發生及減輕相關症狀。此等生物標記之實例包含,但不限於,NADPH依賴酵素(NADPH-dependent enzymes)、硫氧化還原蛋白(thioredoxin,TXN)、硫氧化還原蛋白還原酵素(thioredoxin reductase-1,Txnrd-1)、麩胺酸-半胱胺酸接合酵素次單位(glutamate-cysteine ligase subunit,GCLC)、亞硫酸基轉移酵素1A1(sulfotransferase 1A1,SULT1A1)、第一型血基質氧化酵素(heme oxygenase-1,HMOX1)、麩胺基硫過氧化酶-3(glutathione peroxidase-3,GPx-3)、麩胺基硫轉移酵素theta 2(glutathione S-transferse theta 2,GSTT2)、微粒體麩胺基硫轉移酵素1(microsomal glutathione
S-transferase 1,MGST1)、醛氧化酵素(aldehyde oxidase,AOX1)、醛酮還原酵素1B8(aldo-keto reductase 1B8,Akr1b8)、含黃素之單氧酵素2(flavin-containing monooxygenase 2,FMO2)、Fc受體區域受體III(Fc receptor region receptor III,Fcgr3)、類胰蛋白酵素beta 1(tryptase beta 1,TPSB1)、肥大細胞蛋白分解酵素-6(mast cell protease-6,Mcpt6)、神經細胞表面蛋白-1-alpha(neurexin-1-alpha,NRXN-1)、小眼症相關轉錄因子(microphthalmia-associated transcription factor,MITF)、第二型碘化甲狀腺素脫碘酵素(type II iodothyronine deiodinase,DIO2)、血管生成素-14(angiopoietin-14,Angpt14)、細胞膜表面抗原分化群36(cluster of differentiation,CD36),以及Ntel。與該些生物標記之高水平或異常水平相關之疾病或狀況包含,但不限於,癌症、肺及中樞神經系統之結核、多發性硬化、局部性迴腸炎、動脈粥樣硬化、骨關節炎、氣喘、中風、肺氣腫、糖尿病性腎病變、胎盤之慢性組織細胞絨毛炎、高血壓、腹主動脈瘤、發炎性腸道疾病、慢性鼻竇炎、冠狀動脈疾病及腎臟疾病。
在一些實施例中,該方法包含給予有需要之一受試者服用蘿蔔硫素及含葡聚醣之一種蕈菇萃取物或蕈菇粉末之一組合。在一些實施例中,該方法包含給予有需要之一受試者服用青花菜萃取物或青花菜粉末及含葡聚醣之一種蕈菇萃取物或蕈菇粉末之一組合。在一些較佳實施例中,該方法包含給予該受試者服用蘿蔔苷、芥子酵素、抗壞血酸,以及含葡聚醣之一種蕈菇萃取物或蕈菇粉末之一組合。在較佳實施例中,該些組合在本發明之該些方法中表現出協同作用。
在較佳實施例中,該些組合之一種或多種成分(例如,該蘿
蔔硫素前驅物、能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之該酵素、該酵素增強劑、該蕈菇萃取物或蕈菇粉末;或是該蘿蔔硫素或其衍生物及該蕈菇萃取物或蕈菇粉末;或是該青花菜萃取物或青花菜粉末及該蕈菇萃取物或蕈菇粉末)係以單一組成物或單一劑型之方式一起服用,或者係分開服用,較佳者為在該些成分之治療性質互相重疊之一段時間內服用。在一些實施例中,該些組合之該些成分可以兩個或更多個口服組成物或劑型之方式服用。舉例而言,在一些實施例中,該蘿蔔硫素前驅物、能夠將該蘿蔔硫素前驅物轉換成蘿蔔硫素之該酵素,以及該酵素增強劑係以單一口服劑型之方式服用,而該蕈菇萃取物或蕈菇粉末則以分開或額外之一個或多個口服劑型之方式服用。在較佳實施例中,該組合之該些成分係以單一劑型之方式服用。
在一些實施例中,該組合之服用頻率可為每日一次至十次,較佳者為每日一次至五次,更佳者為每日一次至三次,尤佳者為每日一次。
本申請案所揭露之劑量泛指適用於人類之劑量。劑量之計算,可由熟習本發明所屬技術領域者在評估體重、表面積、代謝率及物種差異後加以判定。
在本說明書中,「受試者」一詞係指任何動物,包含哺乳類及鳥類。哺乳動物包含但不限於人類、狗、貓、馬、牛、駱駝、象、獅、虎、熊、海豹,及兔。在較佳實施例中,該些受試者包含非食用類之哺乳動物,例如人類、貓及狗。
實例1(配方)
以下為本發明之一示範性配方:
配方A
含蘿蔔苷之青花菜種子萃取物(濃度大約12% w/w),50mg至5g
含芥子酵素之冷凍乾燥青花菜芽粉末,25mg至500mg
抗壞血酸,1mg至50mg
含α-葡聚醣之香菇萃取物(濃度大約40% w/w),1mg至250mg
配方B
含蘿蔔苷之青花菜種子萃取物(濃度大約12% w/w),50mg至5g
含芥子酵素之冷凍乾燥青花菜芽粉末,25mg至500mg
抗壞血酸,1mg至50mg
含β-葡聚醣之香菇萃取物(濃度大約20% w/w),1mg至100mg
配方C
一種口服組成物,其包含:
青花菜種子萃取物
青花菜芽萃取物
舞菇萃取物
抗壞血酸
羥丙甲基纖維素(hydroxypropylmethyl cellulose)
微晶纖維素(microcrystalline cellulose)
玉米澱粉
乙基纖維素(ethylcellulose)
交聯羧甲基纖維素鈉(croscarmellose sodium)
丙基纖維素(sodium starch glycolate)
交聯聚乙烯吡咯烷酮(crospovidone)
二氧化矽
海藻酸鈉(sodium alginate)
中鏈三酸甘油脂(medium chain triglycerides)
麥芽糊精(maltodextrin)
油酸(oleic acid)
硬脂酸鎂(magnesium stearate)
硬脂酸(stearic acid)
實例2
一種疏水性交互作用層析(hydrophobic interaction chromatographic,HILIC)
法已研究出來,該方法包含以下條件:
層析管柱:沃特斯公司(Waters Corp.)之BEH(ethylene bridged hybrid)
醯胺,粒徑1.7-μm;內徑2.1mm x 100mm
流動相溶液:20% 10mM之醋酸銨,pH 5.0;80%之乙腈;
分離方式:等位(isocratic)
管柱溫度:70ºC
流率:0.7mL/min
上述條件允許分離五種典型之十字花科硫代葡萄糖苷,包含蘿蔔硫素前驅
物、蘿蔔苷。
實例3
蘿蔔苷消耗量作為抗壞血酸濃度之函數。
在有可變濃度之抗壞血酸(範圍從0至600μmoles/Liter)環
境下,以取自青花菜芽之固定濃度之芥子酵素,將含有約12%(w/w)蘿蔔苷之大約250mg青花菜種子萃取物加以水解。使該些反應混合物保持在38℃之恆溫下60分鐘,並每15分鐘取出等份之實驗試樣(aliquots),以層析方式測定蘿蔔苷之濃度。蘿蔔苷之消耗速率被解釋為蘿蔔苷轉換成蘿蔔硫素之速率。將蘿蔔苷含量減少作為抗壞血酸濃度增加之函數以圖表呈現時產生了一系列之線性圖;該些線性回歸線之斜率反映了蘿蔔苷之消耗速率,其單位為μmoles/minute。明顯的是,在濃度600μmoles/Liter之抗壞血酸環境下,其反應速率較缺少抗壞血酸之調節作用時之反應速率增加到13倍。
蘿蔔苷等莫耳轉換成蘿蔔硫素。
茲進行由兩部分組成之一項實驗,以進一步闡明抗壞血酸在調節芥子酵素活性中的作用。所有溶液均以20mM TBS緩衝液(Tris-buffered
saline)製備,pH值為7.5,該pH值之前已被指出最適於芥子酵素之活性;每一取樣管內裝有精確稱重之冷凍乾燥青花菜粉末100mg作為芥子酵素之來源。該實驗在38℃下進行2小時,每隔30分鐘移除等分之試樣,且蘿蔔苷及蘿蔔硫素之含量皆以HPLC法測定。一種強酸性之反應停止液被用於即刻抑制被移除等份試樣中芥子酵素之進一步活性。一控制樣本不含抗壞血酸,且未以輔助因子協助酵素轉換之進行。
第一部分。在濃度固定為1mmol/Liter之抗壞血酸環境下,加入青花菜種子萃取物(含大約12% w/w之蘿蔔苷),份量從250mg增加至500mg。
第二部分。將青花菜種子萃取物之量固定在250mg,使抗壞血酸之濃度從0.4mmol/Liter改變至3.8mmol/Liter。
下表將蘿蔔苷(GR)及蘿蔔硫素以μmole為單位表示。明顯的是,在幾乎全部的反應混合物中,蘿蔔苷轉換成蘿蔔硫素在前30分鐘內便告完成。然而,控制樣本在沒有抗壞血酸(AA)之刺激作用下所發生之酵素轉換經仔細檢驗後顯示,蘿蔔苷等莫耳轉換成蘿蔔硫素,亦即所消耗之蘿蔔苷之量,相當於所產生之蘿蔔硫素之量。
該實驗之第二部分評定濃度漸增之抗壞血酸對芥子酵素活性之調節作用。可觀察到的是,在芥子酵素之促進下,蘿蔔苷轉換成蘿蔔硫素一開始明顯呈線性,直到抗壞血酸濃度達2mmol/L,之後便顯著趨於平穩。
最後,在該實驗第一部分之30分鐘後,檢驗蘿蔔硫素之產出,其顯示在濃度1mmol/Liter之抗壞血酸環境下,100mg冷凍乾燥青花菜芽粉末中所含固定份量之芥子酵素,能夠以可預測之線性方式產生至少200μmole之蘿蔔硫素。圖1、2、3及4呈現了本實驗之結果。
實例5
蘿蔔苷在有模擬腸液之環境下轉換成蘿蔔硫素。
本實例之實驗使用模擬腸液(SIF)粉末,其係一種商業供應之濃縮物,在組成、pH值及離子強度方面十分接近人類之腸內容物。該實驗使用美國藥典(USP)溶離試驗儀2(Dissolution Apparatus 2(槳形)),有500mL之模擬腸液分配至該試驗儀之六個溶解容器,並以150mg之冷凍乾燥青花菜芽粉末作為芥子酵素之來源。在容器1~4中,抗壞血酸之濃度
從0.25mmol/Liter至1.00mmol/Liter不等;在容器5中,除濃度1mmol/Liter之抗壞血酸外,還懸浮有3.125g之胰酵素(8x USP);在容器6中,除濃度1mmol/Liter之抗壞血酸及3.125g之胰酵素(8x USP)外,還加有雙倍份量之冷凍乾燥青花菜芽粉末(300mg)。在該些容器溫度達到38℃後,將富含蘿蔔苷(12%,w/w)之250mg青花菜種子萃取物加入每一容器,並將以此得到之懸浮液以75RPM之轉速攪動2小時。每隔15分鐘取出等份試樣並測定其蘿蔔硫素含量。圖4呈現蘿蔔硫素較大產出與抗壞血酸較高濃度間之直接相關,尤其是在該實驗之前期階段。
實例6
以下所進行之試驗係為了測定蘿蔔硫素及含有20% β-葡聚醣之一種蕈菇萃取物或蕈菇粉末之組合,對氧化還原酵素Nad(P)H:quinine oxidoreductase(NQO1)基因表現之作用。NQO1會轉譯(encode)一種蛋白質,該蛋白質能夠代謝雌性激素醌類化物,防止雌性激素醌類化物形成會導致突變且最後會癌化之DNA鍵結物(DNA adducts)。NQO1表現之增加有益於乳房、大腸、肝臟、肺臟、皮膚及前列腺之健康。
在該試驗中,將小鼠巨噬細胞株RAW 264.7分別以二甲基亞碸(DMSO,為載體控制組(vehicle control))、蘿蔔硫素(SFN)、β-葡聚醣含量大約20%之舞菇萃取物(Maitake)、蘿蔔硫素及舞菇萃取物之組合,處理24小時。詳細而言,該些細胞株係以下列其中之一加以處理:(i)DMSO(載體控制組)、(ii)0.5μM蘿蔔硫素(SFN)、(iii)250μg/mL舞菇萃取物(Maitake)、(iv)500μg/mL舞菇萃取物(Maitake)、(v)750μg/mL舞菇萃取物(Maitake)、(vi)0.5μM蘿蔔硫素(SFN)及250μg/mL舞菇萃取物
(Maitake)、(vii)0.5μM蘿蔔硫素(SFN)及500μg/mL舞菇萃取物(Maitake),以及(viii)0.5μM蘿蔔硫素(SFN)及750μg/mL舞菇萃取物(Maitake)。NQO-1之基因表現則以定量反轉錄聚合酵素鏈鎖反應(quantitative RT-PCR)加以分析。圖5所呈現之該試驗結果如下表:
該些結果顯示,與各成分單獨存在之情況相較,蘿蔔硫素及舞菇萃取物之組合具有協同作用。此作用被認為超過單純的累加作用。
實例7
以下所進行之試驗係為了測定蘿蔔硫素及含有40% α-葡聚醣之一種香菇萃取物或香菇粉末之組合,對氧化還原酵素Nad(P)H:quinine
oxidoreductase(NQO1)基因表現之作用。
在該試驗中,將小鼠巨噬細胞株RAW 264.7分別以DMSO(載體控制組)、蘿蔔硫素(SFN)、α-葡聚醣含量至少20%之香菇萃取物(Shiitake)、蘿蔔硫素及舞菇萃取物之組合,處理24小時。詳細而言,該些細胞株係以下列其中之一加以處理:(i)DMSO(載體控制組)、(ii)0.5μM蘿蔔硫素(SFN)、(iii)100μg/mL香菇萃取物(Shiitake)、(iv)250μg/mL香菇萃取物(Shiitake)、(v)500μg/mL香菇萃取物(Shiitake)、(vi)0.5μM蘿蔔硫素(SFN)及100μg/mL香菇萃取物(Shiitake)、(vii)0.5μM蘿蔔硫素(SFN)及250μg/mL香菇萃取物(Shiitake),以及(viii)0.5μM蘿蔔硫素(SFN)及500μg/mL香菇萃取物(Shiitake)。NQO-1之基因表現則以定量反轉錄聚合酵素鏈鎖反應(quantitative RT-PCR)加以分析。圖6所呈現之該試驗結果如下表:
該些結果顯示,與各成分單獨存在之情況相較,蘿蔔硫素及香菇萃取物之組合具有協同作用。此作用被認為超過單純的累加作用。
實例8
患有乳癌之一受試者經歷之症狀包括乳房組織受損及乳房疼痛。給予該受試者服用含有蘿蔔苷、芥子酵素、抗壞血酸及一種舞菇萃取物之一藥錠。該藥錠為一種腸溶膜衣配方,會將該些內容物在小腸中釋放。每日服用該藥錠一個月後,該受試者感到多種替代性生物標記(surrogate biomarkers),包含與症狀改善相關之NQO-1,均獲得了調節。
實例9
患有乳癌之一受試者經歷之症狀包括乳房組織受損及乳房疼痛。給予該受試者服用含有蘿蔔苷、芥子酵素、抗壞血酸及一種香菇萃取物之一藥錠。該藥錠為一種腸溶膜衣配方,會將該些內容物在小腸中釋放。每日服用該藥錠一個月後,該受試者感到多種替代性生物標記,包含與症狀改善相關之NQO-1,均獲得了調節。
Claims (7)
- 一種口服組成物,該口服組成物包含蘿蔔硫素或其一種衍生物,以及含有一舞菇萃取物或粉末、一香菇萃取物或粉末及一靈芝萃取物或粉末當中一者或多者之一種蕈菇萃取物或粉末之一種協同增效組合物,其中該衍生物為一種次硫酸硫代氨基甲酸鹽類似物(sulfoxythiocarbamate analogue)或6-甲基亞磺醯基己基異硫氰酸酯(6-methylsulfinylhexyl isothiocyanate)。
- 如申請範圍第1項之口服組成物,其包括含有一種或多種葡聚醣之一舞菇萃取物。
- 如申請範圍第1項之口服組成物,其包括含有β-葡聚醣之一舞菇萃取物。
- 如申請專利範圍第1項之口服組成物,其包括含有一種或多種葡聚醣之一香菇萃取物。
- 如申請專利範圍第1項之口服組成物,其包括含有α-葡聚醣之一香菇萃取物。
- 如申請專利範圍第1項之口服組成物,其包含一舞菇萃取物及一香菇萃取物。
- 如申請範圍第1項之口服組成物,其更包含一種或多種額外成分係自:槲皮素、一種胺基糖(aminosugar)、一種葡萄胺聚醣(glycosaminoglycan)、鱷梨/大豆之不皂化物、一種維生素、咖啡果實、鎂、水飛薊素、原花青素、熊果酸、薑黃素、植物固醇及植物固烷醇所構成之群組中選定。
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261668364P | 2012-07-05 | 2012-07-05 | |
US201261668374P | 2012-07-05 | 2012-07-05 | |
US201261668328P | 2012-07-05 | 2012-07-05 | |
US201261668386P | 2012-07-05 | 2012-07-05 | |
US201261668396P | 2012-07-05 | 2012-07-05 | |
US201261668342P | 2012-07-05 | 2012-07-05 | |
US61/668,374 | 2012-07-05 | ||
US61/668,342 | 2012-07-05 | ||
US61/668,386 | 2012-07-05 | ||
US61/668,328 | 2012-07-05 | ||
US61/668,396 | 2012-07-05 | ||
US61/668,364 | 2012-07-05 | ||
US201361794417P | 2013-03-15 | 2013-03-15 | |
US61/794,417 | 2013-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201717964A TW201717964A (zh) | 2017-06-01 |
TWI637745B true TWI637745B (zh) | 2018-10-11 |
Family
ID=49882601
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102124062A TW201402128A (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及熊果酸之組成物 |
TW105102752A TWI606830B (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素或一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 |
TW102124064A TW201402130A (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及鎂之組成物 |
TW106101594A TWI637745B (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素或包含一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 |
TW102124065A TWI580425B (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素或包含一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 |
TW102124063A TW201402129A (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及一種奶薊萃取物或奶薊粉末之組成物 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102124062A TW201402128A (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及熊果酸之組成物 |
TW105102752A TWI606830B (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素或一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 |
TW102124064A TW201402130A (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及鎂之組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102124065A TWI580425B (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素或包含一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 |
TW102124063A TW201402129A (zh) | 2012-07-05 | 2013-07-04 | 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及一種奶薊萃取物或奶薊粉末之組成物 |
Country Status (11)
Country | Link |
---|---|
US (14) | US20150174093A1 (zh) |
EP (5) | EP3821895A1 (zh) |
JP (10) | JP6548573B2 (zh) |
CN (2) | CN108355136B (zh) |
AU (9) | AU2013286721B2 (zh) |
CA (5) | CA2877329C (zh) |
ES (3) | ES2877326T3 (zh) |
PL (2) | PL3409280T3 (zh) |
RU (2) | RU2666953C2 (zh) |
TW (6) | TW201402128A (zh) |
WO (4) | WO2014008366A2 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10869853B2 (en) * | 2011-10-31 | 2020-12-22 | The Johns Hopkins University | Compositions and methods for treating autism spectrum disorders |
PL3409280T3 (pl) | 2012-07-05 | 2021-10-18 | Nutramax Laboratories, Inc. | Kompozycje zawierające sulforafan i wyciąg lub proszek z ostropestu plamistego |
CN105377252A (zh) | 2013-03-14 | 2016-03-02 | 佛罗里达大学研究基金会 | 利用天然化合物和/或饮食调控癌症 |
US20140275235A1 (en) * | 2013-03-15 | 2014-09-18 | Loic Pierre Deleyrolle | Treatment of Proliferative Disorders |
EP2968990A4 (en) * | 2013-03-15 | 2016-08-24 | Nutramax Lab Inc | COMPOSITIONS COMPRISING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND PHYTOSTEROL OR PHYTOSTANOL |
KR101515573B1 (ko) * | 2014-11-07 | 2015-04-28 | 주식회사 파미니티 | 뉴그린 추출물을 유효성분으로 함유하는 해독용 조성물 |
BR112017012648B1 (pt) | 2014-12-22 | 2020-12-08 | Unilever N.V | composição oral ou tópica e uso de um agonista de fator nuclear eritróide 2 relacionado ao fator 2 e um agonista do receptor hepático x como agentes ativos em uma composição oral ou tópica para beneficiar o crescimento da fibra capilar e/ou induzir o elemento de resposta antioxidante (are) |
JP2018513123A (ja) | 2015-03-12 | 2018-05-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Rorガンマ阻害剤を用いてがんを治療するための方法 |
US11020372B2 (en) | 2015-03-24 | 2021-06-01 | University Of Florida Research Foundation, Incorporated | Dietary and natural product management of negative side effects of cancer treatment |
ES2818179T3 (es) | 2015-06-26 | 2021-04-09 | Plant Bioscience Ltd | Glucorafanina para uso en el tratamiento y/o prevención de la diabetes mellitus |
KR20180014194A (ko) * | 2015-06-26 | 2018-02-07 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 천연 화합물 및/또는 식단을 사용하는 염증의 치료 방법 |
WO2017013239A1 (en) * | 2015-07-22 | 2017-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nrf2 activators for the treatment of mycobacterial infections |
EP3123874B1 (en) * | 2015-07-28 | 2018-05-02 | Fundacíon Tecnalia Research & Innovation | Formulations comprising glucosinolates and myrosinase |
GB201605013D0 (en) * | 2016-03-24 | 2016-05-11 | Inst Of Food Res | S-methylcysteine sulfoxide for prostate cancer treatment |
US11344575B2 (en) * | 2016-08-15 | 2022-05-31 | Summit Innovation Labs, LLC | Vascular calcification prevention and treatment |
US11357250B2 (en) | 2016-08-15 | 2022-06-14 | Summit Innovation Labs LLC | Treatment and prevention of diabetes and obesity |
US10925304B2 (en) * | 2016-12-28 | 2021-02-23 | Productive Aging Laboratory, Co., Ltd. | Method for treating chronic fatigue syndrome, idiopathic chronic fatigue, and fibromyalgia |
JP7057070B2 (ja) | 2017-06-21 | 2022-04-19 | カゴメ株式会社 | 粉末食品、及びその製造方法、並びに粉末食品のミロシナーゼ活性促進方法 |
CA3077235A1 (en) * | 2017-09-28 | 2019-04-04 | Commonwealth Scientific And Industrial Research Organisation | Isothiocyanate containing brassicaceae products and method of preparation thereof |
EP3762005A4 (en) * | 2018-03-05 | 2022-03-30 | Laila Nutraceuticals | SYNERGIC HERBAL COMPOSITIONS FOR THE TREATMENT OF OBESITY AND OVERWEIGHT |
CN116474079A (zh) * | 2019-05-08 | 2023-07-25 | 深圳福山生物科技有限公司 | 包含萝卜硫苷的组合物及其用途 |
WO2022047212A1 (en) * | 2020-08-27 | 2022-03-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating neurodegenerative disorders |
US11801273B2 (en) | 2020-12-23 | 2023-10-31 | Church & Dwight Co., Inc. | Compositions and methods to increase production of isothiocyanates |
CN112574161A (zh) * | 2021-01-19 | 2021-03-30 | 江苏德和生物科技有限公司 | 一种富含egc的非酯型茶多酚的制备方法 |
JP7288474B2 (ja) | 2021-03-10 | 2023-06-07 | プライムプラネットエナジー&ソリューションズ株式会社 | 非水電解質二次電池の製造方法、および負極活物質 |
WO2022251524A1 (en) | 2021-05-26 | 2022-12-01 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and moringa plant components |
US20230364133A1 (en) * | 2022-05-10 | 2023-11-16 | Melaleuca, Inc. | Dietary supplement compositions |
WO2024064264A2 (en) * | 2022-09-21 | 2024-03-28 | Lile Method Research, Llc | Compositions and methods for increasing glutathione levels |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007607A1 (en) * | 1998-08-04 | 2000-02-17 | Kosbab, John, V. | Nutrient and therapeutic compositions for the treatment of cancer |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3442639A1 (de) | 1984-11-22 | 1986-05-22 | Dr. Madaus & Co, 5000 Köln | Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten |
US5032401A (en) * | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5223491A (en) | 1989-11-09 | 1993-06-29 | Donzis Byron A | Method for revitalizing skin by applying topically water insoluble glucan |
US5411986A (en) | 1993-03-12 | 1995-05-02 | The Johns Hopkins University | Chemoprotective isothiocyanates |
JPH07252148A (ja) * | 1994-10-08 | 1995-10-03 | Masahiro Nagahama | 糖尿病治療薬 |
US5576015A (en) | 1995-03-02 | 1996-11-19 | Donzis; Byron A. | Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses |
US5725895B1 (en) | 1995-09-15 | 2000-10-10 | Hopkins J School Of Medicine | Method of preparing food product from cruciferous seeds |
US5686108A (en) * | 1995-09-27 | 1997-11-11 | Amway Corporation | Brassica vegetable supplement and process for manufacture |
JP3041232B2 (ja) | 1995-11-16 | 2000-05-15 | 日本ケミカルリサーチ株式会社 | 癌転移抑制剤 |
JP2918834B2 (ja) | 1995-12-25 | 1999-07-12 | 美穂 田中 | シイタケエキス粉末の製造法 |
JP2859843B2 (ja) | 1996-03-08 | 1999-02-24 | 株式会社雪国まいたけ | マイタケから抽出した抗腫瘍物質 |
US6242018B1 (en) | 1997-04-11 | 2001-06-05 | Johns Hopkins School Of Medicine | Cancer Chemoprotective food products |
WO1999043336A1 (en) | 1998-02-27 | 1999-09-02 | Nutramax Laboratories, Inc. | L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage |
US20010000472A1 (en) | 1998-02-27 | 2001-04-26 | Nutramax Laboratories, Inc. | L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage |
US6521818B1 (en) | 1998-07-01 | 2003-02-18 | John Hopkins School Of Medicine | Development of novel highly chemoprotectant crucifer germplasm |
JP4308350B2 (ja) | 1998-11-27 | 2009-08-05 | 小林製薬株式会社 | シイタケ菌糸体抽出物を含有するlak活性スクリーニング物質およびそれを用いたlak活性スクリーニング法 |
US20030091518A1 (en) | 1999-12-20 | 2003-05-15 | Gilles Pauly | Cosmetic and/or pharmaceutical preparations |
WO2001054673A1 (en) | 2000-01-31 | 2001-08-02 | The University Of British Columbia | Method for preparing and administering medicinal plant material |
US6511675B2 (en) * | 2000-06-12 | 2003-01-28 | Access Business Group International, Llc | Composition and method for correcting a dietary phytochemical deficiency |
CN100522154C (zh) * | 2000-08-21 | 2009-08-05 | 杰德W·费伊 | 异硫氰酸酯类化合物在制备治疗螺杆菌感染的药物中的用途 |
JP3504612B2 (ja) | 2000-12-28 | 2004-03-08 | 株式会社東洋新薬 | 栄養補助食品 |
US6582723B2 (en) | 2001-05-03 | 2003-06-24 | Wayne F. Gorsek | Cancer immune composition for prevention and treatment of individuals |
US8017160B2 (en) * | 2003-08-15 | 2011-09-13 | Russell Jaffe | Enhancement of magnesium uptake in mammals |
JP2005073508A (ja) | 2003-08-28 | 2005-03-24 | Asahi Denka Kogyo Kk | 食用または薬用植物を含有する飲料 |
ITMI20040696A1 (it) | 2004-04-08 | 2004-07-08 | Aboca S P A | Composizioni per tisane arricchite con estratti secchi vegetali |
JP4126053B2 (ja) * | 2004-05-06 | 2008-07-30 | 堯 近藤 | 鹿角霊芝を含有した健康食品の製造方法 |
WO2005107496A1 (ja) | 2004-05-06 | 2005-11-17 | Maruasaen Corporation | 生キノコエキス製造方法、エキス及びエキス配合物 |
RU2292899C2 (ru) | 2004-06-29 | 2007-02-10 | Дмитрий Николаевич Мясников | Средство и способ профилактики и уменьшения неблагоприятных проявлений острой алкогольной интоксикации (варианты) и способ получения средства |
US20060264497A1 (en) * | 2005-03-28 | 2006-11-23 | Zeligs Michael A | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health |
EP1709969A1 (en) | 2005-04-07 | 2006-10-11 | Praktijkonderzoek Plant en Omgeving B.V. | Health promoting dairy and food products containing mushroom glucan produced through fermentation of Grifola frondosa |
KR100661032B1 (ko) * | 2005-04-19 | 2006-12-22 | 주식회사한국야쿠르트 | 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물 |
NZ563852A (en) * | 2005-04-29 | 2011-07-29 | Univ Johns Hopkins | Methods of supressing UV light-induced skin carcinogenesis |
US8124135B2 (en) | 2005-05-24 | 2012-02-28 | Vdf Futureceuticals, Inc. | Compositions and methods for reduction of LDL oxidation |
US7887852B2 (en) * | 2005-06-03 | 2011-02-15 | Soft Gel Technologies, Inc. | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols |
DE102005033616A1 (de) * | 2005-07-19 | 2007-01-25 | Biopro Ag Biological Products | Verfahren zur Herstellung von Extrakten aus Brassica-Arten und ihre Verwendung |
US20070021376A1 (en) * | 2005-07-21 | 2007-01-25 | Suracell, Inc. | Supplement composition and method of use in enhancement of methylation process |
US7597910B2 (en) | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
RU2319494C2 (ru) * | 2005-11-11 | 2008-03-20 | РАНХЕЛЬ Хосе Анхель ОЛАЛДЕ | Синергетическая композиция растительного происхождения (варианты), способ лечения заболеваний с ее использованием |
US8323644B2 (en) | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
MY166532A (en) * | 2006-02-10 | 2018-07-10 | Mannatech Inc | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
JP2007320947A (ja) * | 2006-05-30 | 2007-12-13 | Shonan Institute For Medical & Preventive Science | 血糖値上昇抑制剤 |
JP4677033B2 (ja) | 2006-06-02 | 2011-04-27 | 株式会社ハイマート | マイタケ抽出物及びこれを含む皮脂産生を促進するための組成物 |
WO2008002175A1 (fr) * | 2006-06-29 | 2008-01-03 | Vulf Abramovich Laskin | Régime hebdomadaire destiné aux patients oncologiques et aux personnes ayant une durée de vie remarquablement longue |
US7803605B2 (en) | 2006-07-14 | 2010-09-28 | National Institute Of Advanced Industrial Science And Technology | Breeding method for yeast, yeast and a production method for glycoprotein or beta-glucan |
KR20080030722A (ko) | 2006-10-02 | 2008-04-07 | 신현길 | 브로콜리가루가 첨가된 빵의 제조방법 |
WO2008115583A1 (en) * | 2007-03-21 | 2008-09-25 | John Mini | Herbal treatments |
US20080254055A1 (en) | 2007-04-11 | 2008-10-16 | John Erich Oblong | Compositions for Regulation of Hair Growth |
US20080311192A1 (en) * | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Enteric-Coated Glucosinolates And Beta-Thioglucosidases |
WO2009008006A2 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
CZ305673B6 (cs) | 2007-08-02 | 2016-02-03 | Irel, Spol. S R. O. | Mechanicky upravený plod ostropestřce mariánského a způsob jeho úpravy |
ES2325291B1 (es) | 2007-10-04 | 2010-04-22 | Madaus S A | "uso de un extracto de silybum marianum" |
EP2205237A1 (en) | 2007-10-16 | 2010-07-14 | Johns Hopkins University | Methods for protecting the skin from radiation insults |
WO2009063885A1 (ja) | 2007-11-13 | 2009-05-22 | Heimat Co., Ltd. | マイタケ抽出物及びこれを含むヒアルロン酸(ヒアルロナン)産生を促進するための組成物 |
ITMI20080172A1 (it) * | 2008-02-05 | 2009-08-06 | Bios Line Spa | Formulazioni orali per la protezione delle vie respiratorie con particolare riferimento ai fenomeni infiammatori e neoplastici |
US20090252758A1 (en) * | 2008-04-07 | 2009-10-08 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
US7923044B2 (en) * | 2008-07-15 | 2011-04-12 | Paradise Herbs & Essentials, Inc. | Composition for high-ORAC value dietary supplement |
KR20100016876A (ko) * | 2008-08-05 | 2010-02-16 | 오춘근 | 다이어트 및 당뇨에 유용한 기능성 혼합곡물 |
EP2213280A1 (en) | 2009-01-30 | 2010-08-04 | DSM IP Assets B.V. | Formulations comprising glucosinolate and myrosinase |
CN101514174B (zh) * | 2009-02-24 | 2011-11-02 | 黑龙江八一农垦大学 | 一种从西兰花芽苗菜中提取多功能莱菔硫烷的方法 |
US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
JP2010259424A (ja) * | 2009-05-11 | 2010-11-18 | Hisako Arai | 簡単に摂取できる副食の調理法。 |
WO2011003045A1 (en) * | 2009-07-01 | 2011-01-06 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
WO2011060585A1 (zh) * | 2009-11-20 | 2011-05-26 | 天津天狮生物发展有限公司 | 含有五色果蔬精华的咀嚼片剂及其制备方法 |
WO2011076154A1 (en) | 2009-12-22 | 2011-06-30 | Irel, Spol. S R.O. | Feed supplement based on milk thistle, method of its production and its use |
KR101079643B1 (ko) | 2010-01-12 | 2011-11-04 | 이현재 | 신장 기능 강화용 식품 조성물 및 그 제조방법 |
WO2011099665A1 (ko) | 2010-02-12 | 2011-08-18 | 주식회사 케이씨아이 | 천연 원료 추출물을 포함하는 항균 조성물, 복합 천연 방부제 및 이들의 제조방법 |
US20110206721A1 (en) * | 2010-02-19 | 2011-08-25 | Vijaya Nair | Fermented soy nutritional supplements including mushroom components |
US20120021079A1 (en) | 2010-02-23 | 2012-01-26 | Brett Justin West | Garcinia Mangostana L. and Iridoid Based Formulations |
US20110262595A1 (en) | 2010-04-21 | 2011-10-27 | Naturalife Asia Co., Ltd. | Antioxidant nutritional supplement |
US20110287109A1 (en) * | 2010-05-24 | 2011-11-24 | Max International, Llc | Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products |
DE102010022587A1 (de) * | 2010-05-28 | 2011-12-01 | Wilfried Rühle | Magensaftresistente Zusammensetzung zur oralen Einnahme von pflanzenbasierten Komponenten zur Prävention von Darmkrebs |
CN102450534A (zh) * | 2010-10-26 | 2012-05-16 | 宁波海逸生物科技有限公司 | 一种增强免疫力功能的西灵胶囊配方 |
ES2382299B1 (es) | 2010-11-11 | 2013-05-07 | Consejo Superior De Investigaciones Científicas (Csic) | Polvo vegetal para alimentación y protección vegetal y métodos de preparación. |
NZ589578A (en) * | 2010-11-29 | 2013-03-28 | Comvita Ltd | Cancer Chemoprotective Product including glucosinolate and myrosinase |
CN102526455A (zh) | 2010-12-16 | 2012-07-04 | 天津中敖生物科技有限公司 | 具有清肺化痰功能的家畜用中药组合物及其制备方法 |
CN103458921B (zh) * | 2011-02-22 | 2016-05-11 | 考迪尔种子公司 | 喷雾干燥的黑芥子酶和用于生产异硫氰酸酯的用途 |
WO2012122295A2 (en) * | 2011-03-07 | 2012-09-13 | Ned Biosystems, Inc. | Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin |
US20130045273A1 (en) * | 2011-08-19 | 2013-02-21 | John Cuomo | Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds |
CN102526445B (zh) * | 2011-11-07 | 2013-12-11 | 宁波海逸生物科技有限公司 | 一种增强免疫力、缓解体力疲劳、抗肿瘤功能的保健药物配方 |
PL3409280T3 (pl) * | 2012-07-05 | 2021-10-18 | Nutramax Laboratories, Inc. | Kompozycje zawierające sulforafan i wyciąg lub proszek z ostropestu plamistego |
-
2013
- 2013-07-03 PL PL18182247T patent/PL3409280T3/pl unknown
- 2013-07-03 CA CA2877329A patent/CA2877329C/en active Active
- 2013-07-03 EP EP20209762.2A patent/EP3821895A1/en active Pending
- 2013-07-03 WO PCT/US2013/049267 patent/WO2014008366A2/en active Application Filing
- 2013-07-03 CN CN201810409516.XA patent/CN108355136B/zh active Active
- 2013-07-03 US US14/412,189 patent/US20150174093A1/en not_active Abandoned
- 2013-07-03 ES ES18182247T patent/ES2877326T3/es active Active
- 2013-07-03 AU AU2013286721A patent/AU2013286721B2/en active Active
- 2013-07-03 JP JP2015520673A patent/JP6548573B2/ja active Active
- 2013-07-03 WO PCT/US2013/049261 patent/WO2014008361A2/en active Application Filing
- 2013-07-03 CA CA2877338A patent/CA2877338C/en active Active
- 2013-07-03 EP EP13812796.4A patent/EP2849736B1/en active Active
- 2013-07-03 US US14/412,191 patent/US10960057B2/en active Active
- 2013-07-03 CA CA2877356A patent/CA2877356C/en active Active
- 2013-07-03 US US14/412,176 patent/US10688158B2/en active Active
- 2013-07-03 EP EP19189657.0A patent/EP3666277A1/en active Pending
- 2013-07-03 WO PCT/US2013/049224 patent/WO2014008341A2/en active Application Filing
- 2013-07-03 WO PCT/US2013/049248 patent/WO2014008353A2/en active Application Filing
- 2013-07-03 PL PL13812796T patent/PL2849736T3/pl unknown
- 2013-07-03 RU RU2015103499A patent/RU2666953C2/ru active
- 2013-07-03 CN CN201380035766.7A patent/CN104427981B/zh active Active
- 2013-07-03 EP EP13813686.6A patent/EP2849737B1/en active Active
- 2013-07-03 ES ES13812796T patent/ES2700223T3/es active Active
- 2013-07-03 ES ES13813686T patent/ES2755757T3/es active Active
- 2013-07-03 EP EP18182247.9A patent/EP3409280B1/en active Active
- 2013-07-03 CA CA3112680A patent/CA3112680C/en active Active
- 2013-07-03 JP JP2015520676A patent/JP6436443B2/ja active Active
- 2013-07-03 AU AU2013286713A patent/AU2013286713B2/en active Active
- 2013-07-03 CA CA2877393A patent/CA2877393C/en active Active
- 2013-07-03 US US14/412,180 patent/US20150174213A1/en not_active Abandoned
- 2013-07-03 RU RU2015103498A patent/RU2680387C2/ru active
- 2013-07-04 TW TW102124062A patent/TW201402128A/zh unknown
- 2013-07-04 TW TW105102752A patent/TWI606830B/zh active
- 2013-07-04 TW TW102124064A patent/TW201402130A/zh unknown
- 2013-07-04 TW TW106101594A patent/TWI637745B/zh active
- 2013-07-04 TW TW102124065A patent/TWI580425B/zh active
- 2013-07-04 TW TW102124063A patent/TW201402129A/zh unknown
-
2014
- 2014-12-30 US US14/586,765 patent/US9421183B2/en active Active
- 2014-12-30 US US14/586,698 patent/US20150118305A1/en not_active Abandoned
- 2014-12-30 US US14/586,711 patent/US20150118304A1/en not_active Abandoned
- 2014-12-30 US US14/586,704 patent/US20150118306A1/en not_active Abandoned
-
2016
- 2016-08-23 US US15/244,374 patent/US10583178B2/en active Active
-
2018
- 2018-06-15 AU AU2018204283A patent/AU2018204283B2/en active Active
- 2018-06-25 AU AU2018204604A patent/AU2018204604C1/en active Active
- 2018-11-06 JP JP2018208602A patent/JP6777366B2/ja active Active
- 2018-11-22 JP JP2018219617A patent/JP2019023245A/ja active Pending
-
2019
- 2019-12-03 US US16/701,644 patent/US11654186B2/en active Active
-
2020
- 2020-05-04 US US16/865,529 patent/US11224639B2/en active Active
- 2020-05-14 JP JP2020085417A patent/JP7068383B2/ja active Active
- 2020-08-14 AU AU2020217440A patent/AU2020217440B2/en active Active
- 2020-08-28 AU AU2020223773A patent/AU2020223773B2/en active Active
- 2020-08-31 US US17/007,067 patent/US20210008176A1/en active Pending
- 2020-10-06 JP JP2020168976A patent/JP7109132B2/ja active Active
- 2020-11-27 JP JP2020196733A patent/JP7232806B2/ja active Active
-
2021
- 2021-02-18 US US17/178,664 patent/US12064471B2/en active Active
- 2021-12-23 US US17/560,494 patent/US20220118062A1/en active Pending
-
2022
- 2022-02-17 JP JP2022022783A patent/JP2022059053A/ja active Pending
- 2022-06-02 AU AU2022203801A patent/AU2022203801A1/en not_active Abandoned
- 2022-07-14 JP JP2022113426A patent/JP7458443B2/ja active Active
-
2023
- 2023-07-26 AU AU2023208131A patent/AU2023208131A1/en active Pending
- 2023-12-11 JP JP2023208549A patent/JP2024023619A/ja active Pending
-
2024
- 2024-07-31 AU AU2024205248A patent/AU2024205248A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007607A1 (en) * | 1998-08-04 | 2000-02-17 | Kosbab, John, V. | Nutrient and therapeutic compositions for the treatment of cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI637745B (zh) | 包含蘿蔔硫素或包含一種蘿蔔硫素前驅物及一種蕈菇萃取物或蕈菇粉末之組成物 | |
US20220387535A1 (en) | Compositions comprising sulforaphane or a sulforaphane precursor and moringa plant components |